P age 1 of 59 Protocol Version 1.4 
Protocol T itle: Alvelestat ( MPH966) for t he Treatment of AL pha-1 ANT itrypsi n Deficiency  (ATALANTa) 
A Phase 2, multicenter , doubl e-blind, r andomized, pl acebo- controlled study t o eva luate efficacy, safety, and 
tolerability of al velestat ( MPH966) i n alpha-1 antitrypsin deficiency    
IND: 101,534 
NCT i dentifier: [STUDY_ID_REMOVED] 
Compound Number: Alvelestat/MPH966 (formerly A ZD9668) 
Sponsor Name and Legal Registered Address: National Ins titutes of Health (NIH)/National Center for 
Advancing Translational Scienc es (NCATS), Bethesda, MD  
Document Date: 16/Feb/2021
 Protocol Version 1.4  
 
 Page 2 of 59 Table of Contents  
1. Synopsis  .........................................................................................................................4  
2. Schedule of Activities (SOA)  ....................................................................................6  
3. Introduction ...................................................................................................................7  
3.1.  Background  .....................................................................................................................7  
3.2.  Study Rationale  ..............................................................................................................8  
4. Objectives and Endpoints  .........................................................................................9  
5. Study Design  ...............................................................................................................11  
5.1.  Overall Design  ..............................................................................................................11  
5.2.  Number of Participants  ................................................................................................12  
5.3.  End of Study Definition  ................................................................................................12  
5.4.  Scientific Rationale for Study Design  ........................................................................12  
5.5.  Justification for Dose  ...................................................................................................12  
5.6.  Preclinical Safety Studies  ...........................................................................................13  
5.7.  Clinical Safety Studies  .................................................................................................13  
5.8.  Benefit -Risk Assessment  ............................................................................................14  
6. Study Population ........................................................................................................16  
6.1.  Inclusion Criteria  ...........................................................................................................16  
6.2.  Exclusion Criteria  .........................................................................................................16  
6.3.  Lifes tyle Restrictions  ....................................................................................................18  
6.3.1.  Meals and Dietary Restrictions  ..................................................................................18  
6.3.2.  Alcohol and Tobacco  ...................................................................................................18  
6.3.3.  Activity  ............................................................................................................................18  
6.4.  Screen Failur es ............................................................................................................18  
7. Treatments  ...................................................................................................................19  
7.1.  Treatments Administered  ............................................................................................19  
7.2.  Method of Treatment Assignment  .............................................................................19  
7.3.  Blinding  ..........................................................................................................................19  
7.4.  Preparation/Handling/Storage/Accountability  ..........................................................20  
7.5.  Treatment Compliance  ................................................................................................20  
7.6.  Concomitant Therapy  ..................................................................................................20  
7.7.  Treatment After the End of the Study  .......................................................................21  
8. Discontinuation Criteria  ...........................................................................................22  
8.1.  Discontinuation of Study Treatment  ..........................................................................22  
8.1.1.  Temporary Discontinuation  .........................................................................................24  
8.1.2.  Re-challenge  .................................................................................................................24  
8.2.  Discontinuation From the Study  .................................................................................24  
8.3.  Lost to Follow -up ..........................................................................................................24  
9. Study Assessments and Procedures  ...................................................................25  
9.1.  Key Screening Assessments  .....................................................................................26  
9.2.  Efficacy Assessments  .................................................................................................26  
9.2.1.  Blood, Sputum, and Bronchoalveolar Lavage Biomarkers  ....................................26  
9.2.2.  SGRQ -C.........................................................................................................................27  
9.2.3.  COPD Assessment Test (CAT)  .................................................................................27  
 Protocol Version 1.4  
 
 Page 3 of 59 9.2.4.  Modified Medical Research Council (MMRC)  ..........................................................27  
9.2.5.  San Diego Breath Questionnaire (SOBQ)  ................................................................28  
9.2.6.  Pulmonary Function Testing/Spirometry  ..................................................................28  
9.2.7.  Daily respiratory symptom scores and peak flow by electronic diary  ..................28  
9.3.  Safety Assessments  ....................................................................................................28  
9.3.1.  Physical Examinations  ................................................................................................28  
9.3.2.  Vital Signs  ......................................................................................................................28  
9.3.3.  Clinical Safety Laboratory Assessments  ..................................................................29  
9.3.4.  Data Safety Monitoring Board  ....................................................................................29  
9.4.  Adverse Events  ............................................................................................................30  
9.4.1.  Time Period and Frequency for Collecting AE and SAE Information  ..................30  
9.4.2.  Follow- up of an AE and/or SAE  .................................................................................30  
9.4.3.  Adverse Events of Special Interest  ...........................................................................30  
9.4.4.  Regulatory Reporting Requirements for SAE  ..........................................................31  
9.4.5.  Pregnancy  .....................................................................................................................31  
9.5.  Treatment of Overdose ...............................................................................................32  
9.6.  Pharmacokinetics  .........................................................................................................32  
9.7.  Pharmacodynamics  .....................................................................................................32  
10. Statistical Considerations .......................................................................................33  
10.1.  Sample Size Determination  ........................................................................................33  
10.2.  Populations for Analyses  ............................................................................................33  
10.3.  Statistical Analyses  ......................................................................................................34  
10.3.1 . Efficacy Analyses  .........................................................................................................34  
10.3.2.  Safety Analyses  ............................................................................................................35  
10.3.3.  Other Analyses  .............................................................................................................36  
10.3.4.  Interim Analyses  ...........................................................................................................36  
11. References  ...................................................................................................................37  
12. Appendices  ..................................................................................................................40  
Appendix 1:  Abbreviations, Trademarks & Glossary  .....................................................41  
Appendix  2:  Clinical Laboratory Tests  ...............................................................................46  
Appendix 3:  Study Governance Considerations  .............................................................47  
Appendix 4:  Adverse Events: Definitions and Procedures for Recording, 
Evaluating,  Follow -up, and Reporting  ..................................................................50  
Appendix  5:  Contraceptive Guidance and Collection of Pregnancy Information  ..54 
Appendix  6:  Study Organization  ..........................................................................................57  
Appendix  7:  Summary of Versions and Changes  ...........................................................59  
 
 Protocol Version 1.4  
 
 Page 4 of 59 1. Synopsis 
 
Protocol Title:  Alvelestat ( MPH966) for the Treatment of AL pha-1 ANTitrypsin Deficiency (ATALANTa)  
 
Rationale :  
 Alpha- 1 antitrypsin deficiency (AATD) is the most common genetic cause of chronic obstructive pulmonary 
disease (COPD) and early -onset emphysema.  AATD is characterized by low AAT levels; leading to excessive 
neutrophil elastase (NE) mediated lung destruction.  Current treatment requires the periodic infusion of  pooled 
AAT derived from human plasma, but this therapeutic approach (termed augmentation)  does not definitively 
slow the rate of lung function decline  and is very expensive.   In addition, it is not clear that the currently 
recommended  dose for augmentation fully controls lung inflammation and destruction.   Alvelestat (MPH966, 
formerly AZD9668)  is a potent, s elective, and rev ersible, o ral inhibi tor of  human NE. Suppr ession of NE is 
expected to r educe lung damage and may slow dis ease progress ion. This stud y is to establish proof  of clinical 
conce pt by invest igating the m echanistic effect and safety of alvelestat (MPH966)  in patients with AA TD.  
 Overall Design:  
 
This is a P hase 2, mu lticenter, doubl e-blind, randomized (1:1),  placebo-controll ed, 12 -week, proof-of-concept 
study to ev aluate  the safety and tolerability as well as the mech anistic effect of oral admin istration of  alvelestat 
(MPH966)  in subjec ts wi th confi rmed AATD defined as Pi*ZZ, Pi*SZ, Pi*null, or another rare 
phenotype/genotype known to be associated with either  low (serum AAT level <11 μM or <57.2 mg/dL) or 
functionally impaired AAT including “ F” or “I” mutations . 
 
Objectives and Endpoint s: 
 
Objective  Endpoint  
Primary  
• To evaluate  the effect of a lvelestat (MPH966)  
administered twice d aily (bid) for 12 weeks on 
blood ma rkers of neutrophil elastase  activity • Within-individual %  change from ba seline in 
plasma de smosine/isodesmos ine at end of 
treatment with MPH966  
• To evaluate  the safety and tolerability of alvelestat 
(MPH966)  administered twice d aily (bid) for 12 
weeks  • Numb ers and %  of subj ects who experience at 
least 1 treatment -emergent adverse event 
• Adverse events of sp ecial intere st (liver function 
abnorm alities, corrected QT in terval/cardiac, 
infections, and neutrope nia) 
Secondary  
• To evaluate the effect of alvelestat (MPH966)  on 
other  blood ph armacodynamic markers of  
neutrophil activation and elastase activity • Change from ba seline in p lasma 
desmosine/isodesmos ine at end of tr eatment 
compar ed to pl acebo 
• Change from baseline in blood Aα -Val360, NE, EL-
NE, Proteinase 3, and Cathepsin B  at end of 
treatment  compared to placebo 
• To evaluate the effect of alvelestat (MPH966)  on 
blood biom arkers of lung tissue d egradation • Change from ba seline in blood EL-CG, EL -P3, 
PGP, C6M, C1M, and P RO-C6, at end of 
treatment compa red to p lacebo 
 Protocol Version 1.4  
 
 Page 5 of 59 Objective  Endpoint  
• To evaluate the effect of alvelestat (MPH966)  on 
biomarkers of infl ammation in bl ood • Change from baseline in blood high sensitivity C 
reactive protein, interleukin [ IL]-6, IL -8, IL -1β, 
RANTES, fibrinogen, MMPs, and MPO  at end of 
treatment  compared to placebo 
• To evaluate the effect of alvelestat (MPH966)  on 
neutrophil activation, elastase, and inflammatory 
activity in lung • Change from baseline in  
desmosine/isodesmosine,  NE, NE activity, Aα -
Val360, EL-NE, Proteinase 3, and Cathepsin B; 
inflammatory biomarkers (IL- 6, IL-8, IL- 1β, LTB4, 
RANTES , PGP ) at end of treatment in 
bronchoalveolar lavage (BAL)  compared to 
placebo 
• Change from baseline in 
desmosine/isodesmosine, NE, NE activity, Aα -
Val360, EL-NE, Proteinase 3, and Cathepsin B , and 
inflammatory biomarkers (IL- 6, IL-8, IL- 1β, LTB4, 
RANTES , PGP ) at end of treatment in induced 
sputum  compared to placebo 
Exploratory  
• To evaluate the effect of alvelestat (MPH966) on 
pulmonary function • Change from baseline in pre- and post -
bronchodilator forced expiratory volume in 1 
second ( FEV 1), forced vital capacity ( FVC), 
FEV 1/FVC ( total and percent predicted) , and 
maximal mid -expiratory flow at end of treatment  
• To evaluate the effect of alvelestat  (MPH966)  on 
respiratory symptoms , breathlessness, and health 
status  • Change from bas eline in St. Ge orge’s Respiratory 
Questionna ire (SGR Q), COPD Assessment Test 
(CAT), Modified Medical Research Council 
Questionnaire (MMRC), San Diego Breath 
Questionnaire (SOBQ)  and daily symptom scores  
• To evaluate PK efficacy relationships in AATD  • PK/pharmacodynamic (PD)  relationship with 
efficacy biomarkers in blood and sputum  
 
 
 Protocol Version 1.4  
 
 Page 6 of 59 2. Schedule of Activities (SOA)  
Visit #  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit  7 Visit 8  Visit 9  Visit 10  Visit 11  Visit 12  
Visit Description  Pre-
bronch/ 
Screen  Baseline 
bronch  Randomize  Safety 
F/U Safety 
F/U 4 week 
F/U Safety 
F/U 8 week 
F/U Safety F/U 
and Pre-
bronch  End of study 
bronch  Study 
End Washout End  
Week (from 
randomization)  -4 to 0 -1 0 +1 +2 +4 +6 +8 +10 +11 +12 +16 
Randomization    X          
Baseline history  X            
Physical exam  X X X X X X X X X X X X 
Interim history and 
adverse event 
recording   X X X X X X X X X X X 
Blood draw 
(routine/safety)  X   X X X X X X  X X 
Blood draw 
(biomarkers)  X  X   X  X   X X 
Blood (PK)    X@ X X X  X X  X  
Pregnancy test  X  X X X X X X X  X X 
ECG  X  X@ X X X  X X  X X 
Sputum biomarkers  X          X  
Spiro - pre and post BD    X   X     X X 
Spiro – post BD  X        X    
PROs#   X   X     X X 
Bronchoscopy   X        X   
Phone contact   X 
 (day after)         X  
(day after)    
Electronic diary  X  X X X X X X X X X X 
 
 
 #Patient reported outcomes to include Modified Medical Research Council questionnaire (MMRC), COPD assessment test (CAT), St George Respiratory  Questionnaire (SGRQ), 
San Diego Shortness of Breath Questionnaire; @ pre- dose and between 1 and 2 hours post -dose 
 Protocol Version 1.4  
 
 Page 7 of 59 3. Introduction  
 
3.1. Background 
 
COPD affects nearly 24 million individuals and is the fourth leading cause of death in the United States1-4.  COPD 
is a heterogeneous disease characterized by progressive airflow obstruction, excessive inflammation, and 
protease/anti -protease imbalance 5,6.  AATD is the most common genetic cause of COPD and emphysema, 
accounting for 1 -4% of cases of COPD in the United States and affecting between 70,000- 100,000 individuals 7-
9.  AAT is encoded by the SERPINA1 gene and mutations in SERPINA1 cause absence or misfolding of the AAT 
protein, resulting in severely reduced plasma and lung levels of AAT.  The most common variants conveying 
increased risk for COPD associated with AATD are the Pi*ZZ and Pi*(null)  (null) phenotypes, accounting for very 
low or absent AAT respectively.  In contrast to the general COPD population, individuals with AATD have early -
onset severe emphysema, a more rapid decline in lung function, and an increased risk for liver dysfunction 10.  
The disease often affects people in the fourth and fifth decades of life, leading to substantial loss of productivity and societal contributions
7.  Current therapies for AATD include the use of bronchodilators, inhaled 
corticosteroids, and intravenous AAT augmentation using pooled, human plasma derived AAT.  AAT 
augmentation is indicated for individuals with emphysema and AATD, including individuals with the Pi*ZZ, Pi*SZ, 
Pi*Z (null), or Pi*(null)  (null) mutations.  AAT augmentation has been shown to slow the loss of lung parenchyma 
as measured by CT lung density, but unfortunately does not definitively affect lung function decline, respiratory symptoms, exacerbations, or surviv al
9,11.  Further, AAT augmentation is very expensive with direct annual costs 
exceeding $100,000 per patient including the costs associated with technical expertise required for repeated 
intravenous infusion.   Recent studies also suggest that the cur rently recommended dose of augmentation does 
not adequately control NE activity, lung inflammation and consequent lung destruction pointing to the need for 
additional NE inhibition to improve outcomes12.    
 
The mechanisms by which AATD leads to COPD and emphysema are based primarily on the paradigm of 
protease -antiprotease imbalance 7,8,13.  AAT is a member of the serine protease inhibitor superfamily of proteins 
which play a role in inactivating NE and other proteases14,15.  AAT reacts with NE much more readily than other 
proteases, including proteinase 3 ( PR3), cathepsin G ( CatG ), and trypsin, and in the lung plays a major role in 
mitigating against NE -mediated elastolysis.  In AATD, individuals not only have quantitatively less AAT, but the 
enzyme is less effective in inhibiting NE16.  NE is a protease stored in the azurophilic  granules of neutrophils and 
causes more robust proteolysis and connective tissue degradation compared to other proteases, including C atG 
and PR3, contained in the same azurophilic granules 17.  Under normal c ircumstances, NE is regulated by AAT, 
however, in conditions like COPD, and in particular AATD, the extracellular free enzyme NE concentration 
exceeds the buffering capacity of AAT 7,15.  Thus, NE causes direct lung tissue destruct ion and initiates a cascade 
resulting in pulmonary inflammation, mucus overproduction, and further damage to lung tissue and extracellular 
matrix18,19.     
 
Elastin is responsible for the elasticity of the lungs and is the substrate for NE20-22.  Elastin is a highly insoluble 
protein formed by cross -linking tropoelastin with desmosine and isodesmosine (collectively referred to as DES).  
Elastin degradation generates several elastin fragments, including DES20.  As these molecules are found 
exclusively in mature elastin in humans, they are useful biomarkers for measuring lung elastin degradation and 
have been measured in lung tissue, sputum, bronchoalveolar lavage (BAL), ur ine, and blood in patients with 
AATD20,23 -25.  DES as well as other NE -specific markers of elastin or collagen turnover (EL -NE) are associated 
with CT emphysema, lung function, and with other markers of inflammation in COPD and in AATD 26-30.  Further,  
AAT augmentation therapy has been demonstrated to reduce DES levels, validating their use as a marker for target modulation in trials targeting NE 
31. 
 
MPH966 (previously named AZD9668)  is a potent, selective, and orally available neutrophil elastase (NE)  
inhibitor32,33.  It has been developed as treatment for pulmonary diseases characterized by increased protease 
activity and neutrophilic inflammation, including bronchiectasis, cystic fibrosis (CF), and COPD33-38. In Phase 2 
clinical trials, MPH966 improved lung function in bronchiectasis, reduced markers of elastin degradation in CF, 
and reduced inflammatory markers in non- AATD patients with COPD.  MPH966 was well tolerated in these trials 
 Protocol Version 1.4  
 
 Page 8 of 59 and no significant safety concerns were raised. However, in  the COPD studies, MPH966  failed to achieve the 
primary efficacy endpoint of lung function improvement, due in part to the heterogeneous nature of population 
enrolled33,34.  AATD leads to the only true unique endotype in COPD 19,39 and is caused by a genetic mutation 
leading to unopposed NE activity which in turn promotes accelerated lung destruction and early -onset 
emphysema7,8.  Thus, AATD related COPD is the most ideally suited disease to test anti -NE therapy, and this 
project will examine the potential benefit of MPH966.  
 MPH966 has high binding affinity and potently inhibits NE activity with an IC
50 of 12 nM and K i of 9.4 nM for 
human NE32.  MPH966  abrogated acute lung injury in mice and rats and decreased pulmonary inflammation 
(neutrophils and IL- 1b) in smoking injury models32.  In chronic smoke exposure models in guinea pigs, MPH966  
prevented airspace enlargement and alveolar remodeling.  In ex vivo  experiments, MPH966  inhibited zymosan -
stimulated NE activity in human blood, with an IC 95 at plasma concentrations of 300nM32.  A detailed descripti on 
of the chemistry, pharmacology, efficacy, and safety of alvelestat (MPH966) is provided in the Investigator 
Brochure ( Version 12 ).  
 
To date, 12 clinical trials have been conducted using MPH966 in non -CF bronchiectasis, CF, bronchiolitis 
obliterans syndrome, and COPD.  Although none of these trials achieved their primary endpoint, significant 
improvements in FEV 1 were observed in non- CF bronchiectasis and improvement in inflammatory markers were  
observed in CF and in non- AATD related COPD.  These trials compared placebo to MPH966 60mg twice per 
day and plasma MPH966 levels averaged 200nM, suggesting the 60mg dose was at the lower end of the dose 
range to achieve adequate target engagement.  Thus,  a higher dose of MPH966 is needed to achieve the IC 95 
(plasma MPH966  concentration of >300nM). In all previous trials, MPH966 was well tolerated with no treatment 
emergent significant adverse events, ECG or vital sign changes, and no dose related liver function abnormalities 
were observed.  
   
The scientific premise that NE inhibition ameliorates ongoing elastolysis in AATD will be tested.  If MPH966  
blocks NE activity in the lungs of AATD patients with PI*ZZ, Pi*SZ, or PI*(Null)  (Null) phenotypes, we predi ct that 
it will provide the first disease -modifying treatment in AATD and provide a paradigm shifting oral therapeutic 
strategy.  This would transform the care of an orphan disease in a patient population with an unmet medical 
need.   The first stage in the development of alvelestat  (MPH966)  in AATD -related emphysema is this proof -of-
concept trial. The results of this study will determine progression to phase 3 clinical efficacy  studies.     
 
3.2. Study Rationale  
 
The aims of this study are to build on the previous alvelestat  (MPH966 ) clinical experience and to confirm 
mechanistic efficacy through elastase inhibition in the AATD population  and investigate the safety and tolerability 
of alvelestat  (MPH966)  in the target population. Clinical efficacy endpoint studies in AATD -related lung disease  
often  involve longer -term studies  and are therefore inappropriate for decision making at the early stages of 
clinical development. The availability of biomarkers of elastolysis , which have been investigated in AATD, 
correlate with lung damage,  and show treatment response over periods of 4 to 12 weeks  23,25,31, enables a study 
design to demonstrate mechanistic e ffects over an appropriate time  period for a proof -of-concept trial. Greater 
efficacy and clinical benefit is expected by targeting patients with AATD -related lung disease, in which neutrophil 
elastase is considered the key pathogenic driver, and by using a dose of alvelestat (MPH966) to maintain neutrophil elastase  inhibition throughout the 24- hour period.  
 
Biomarkers of inflammation and lung matrix breakdown will be used to provide evidence that the inhibitory effec t 
of alvelestat  (MPH966)  on neutrophil elastase may deliver potential clinical benefit demonstrated by effects on 
the pathogenic progresses that drive disease progression. This potential will be tested in patients receiving 
augmentation, which is the standard of care in many countries, as well as in those not receiving augmentation. 
These efficacy data in combination with safety and tolerability will be used to make progression decisions on 
alvelestat  (MPH966 ) development in AATD .  
 Protocol Version 1.4  
 
 Page 9 of 59 4. Objectives and Endpoints 
 
Objective  Endpoint  
Primary  
• To evaluate  the effect of alvelestat (MPH966)  
administered twice d aily (bid) for 12 weeks  on 
blood ma rkers of neutrophil elastase  activity • Within-individual %  change from b aseline in plasma 
desmosine/isodesmos ine at end of tr eatment with 
MPH966  
• To evaluate  the safety and tolerability of 
alvelestat (MPH966)  administered twice d aily 
(bid) for 12 weeks  • Numb ers and %  of subj ects who experience at least 1 
treatment -emergent adverse event 
• Adverse events of spe cial intere st (liver fun ction 
abnorm alities, corrected QT in terval/cardiac, 
infections, and neutrope nia) 
 
Secondary 
• To evaluate  the effect of alvelestat (MPH966)  
on other  blood pharmacodynamic markers of 
neutrophil activation and elastase activity • Change from bas eline in p lasma 
desmosine/isodesmos ine at end of tr eatment 
compar ed to pl acebo 
• Change from baseline in blood Aα- Val360, NE, EL -NE, 
Proteinase 3, and Cathepsin B at end of treatment 
compared to placebo  
• To evaluate  the effect of alvelestat (MPH966)  
on blood biom arkers of  lung tissue 
degradation • Change from base line in blood EL- CG, EL -P3, PGP, 
C6M, C1M, and P RO-C6, at end of tr eatment 
compar ed to pl acebo 
• To evaluate  the effect of alvelestat (MPH966)  
on biom arkers of infl ammation in bl ood • Change from baseline in blood high sensitivity C 
reactive protein, interleukin [IL] -6, IL -8, IL -1β, 
RANTES, fibrinogen, MMPs, and MPO at end of 
treatment compared to placebo 
• To evaluate  the effect of alvelestat (MPH966)  
on ne utrophil activation, elastase, and 
inflammatory activity in lung  • Change from baseline in  desmosine/isodesmosine, 
NE, NE activity, Aα -Val360, EL-NE, Proteinase 3, and 
Cathepsin B; inflammatory biomarkers (IL- 6, IL-8, IL-
1β, LTB4, RANTES, PGP) at end of treatment in 
bronchoalveolar lavage (BAL) compared to placebo  
• Change from baseline in desmosine/isodesmosine, 
NE, NE activity, Aα -Val360, EL-NE, Proteinase 3, and 
Cathepsin B, and inflammatory biomarkers (IL -6, IL-8, 
IL-1β, LTB4, RANTES, PGP) at end of treatment in 
induced sputum compared to placebo  
Exploratory  
 Protocol Version 1.4  
 
 Page 10 of 59 Objective  Endpoint  
• To evaluate the effect of alvelestat (MPH966) 
on pulmonary function  • Change from baseline in pre -and post -bronchodilator 
forced expiratory volume in 1 second (FEV 1), forced 
vital capacity (FVC), FEV 1/FVC (total and percent 
predicted), and maximal mid- expiratory flow at end of 
treatment  
• To evaluate the effect of alvelestat (MPH966) 
on respiratory symptoms, breathlessness, 
and health status  • Change from ba seline in S t. Ge orge’s Re spiratory 
Questionna ire (SGR Q), COPD Assessment Test 
(CAT), Modified Medical Research Council 
Questionnaire (MMRC), San Diego Breath 
Questionnaire (SOBQ)  and daily symptom scores  
• To evaluate PK efficacy relationships in 
AATD  • PK/pharmacodynamic (PD) relationship with efficacy 
biomarkers in blood and sputum  
 
 Protocol Version 1.4  
 
 Page 11 of 59 5. Study Design   
 
5.1. Overall  Design   
 
This will be a multicenter , double- blind, randomi zed, placebo -controlled trial.  One dose  of alvelestat  (MPH966) , 
120 mg  bid, will be tested against placebo. These doses are based on PK and PD modelling of alvelestat  
(MPH966)  inhibition of human neutrophil elastase.   
 
The participants will be those patients with the AATD  at risk for emphysema (Pi*ZZ, Pi*SZ, Pi*null, or another 
rare phenotype/genotype known to be associated with either  low (serum AAT level <11 μM or <57.2 mg/dL ) or 
functionally impaired AAT including “ F” or “I” mutations )  
 
Following a screening period of up to 4 weeks , patients will be dosed with study treatment  or placebo fo r 12 
weeks, with a subsequent 4 -week follow -up period for safety and determination of the offset of the mechanistic 
effect of MPH966 on the primary endpoint (desmosine/isodesmosine) . 
 The study is divided into 3 phases:  a screening phase, treatment phase, and washout phase as detailed below:  
Figure 1: Study Schematic  
 
 
• A screening period from Week  -4 to Day -1.  Baseline safety assessments and measurement of DES in 
blood, sputum , and BAL (in those who consent to bronchoscopy) will occur prior to randomization and 
treatment allocation.  
 
• A treatment period consist ing of alvelestat (MPH966)  120mg bid or pl acebo for 12 w eeks.  Safety 
assessments including tests of liver function, ECG, and chemistries will be assessed at the week 1 and week 
2 visits and then bi -weekly for the remainder of the 12- week treatment period.  Blood will be collected at the 
Week 4 , 8, and 12 visit for biomarker analysis.  Sputum will be collected at the week 12 visit. Follow -up BAL 
will be collected at week 11.   
 
• A washout period from Week 12 to Week 16 .  Blood will be collected for biomarker analysis  at week 16 . 

 Protocol Version 1.4  
 
 Page 12 of 59  
5.2. Number of P articipant s 
 
A maximum of 66 participants will be randomi zed so that approximately 60 evaluable participants complete the 
study.   
 5.3. End of Study Definition  
 
The end of the study is def ined as the date of all data being entered into the study database and the database 
being locked and ready for analysis . 
 
5.4. Scientific Rationale for  Study Design   
 
The aims of this study are to build on the previous alvelestat  (MPH966 ) clinical experience and to confirm its 
mechanistic efficacy through elastase inhibition in the AATD population and to investigate the safety and 
tolerability of alvelestat  (MPH966)  in the target population.  
 
Clinical efficacy endpoint studies in AATD -related lung disease involve long- term treatment due to the slow rate 
of structural  lung and functional decline and are therefore inappropriate for decision making at the early stages 
of drug development. The availability of biomarkers of neutrophil elastase activity (such as 
desmosine/isodesmosine and Aα- Val
360), which have been investigated in AATD, correlate with lung damage 
and show treatment response over periods of 4 to 12 weeks, enables a study design to demonstrate mechanistic 
effects over an appropriate time period for a proof -of-concept trial40. Biomarkers of inflammation and lung matrix 
breakdown will be used to provide evidence that the inhibitory effect of alvelestat  (MPH966 ) on neutrophil 
elastase may deliver clinical benefit demonstrated by effects on the pathogenic processes that drive disease 
progression. These efficacy data , in combination with information about safety and tolerability , will be used to 
make progression decisions on further alvelestat  (MPH966)  development in AATD.  
 
5.5. Justification for Dose  
 
Single oral doses of alvelestat  (MPH966)  2 mg to 150 mg have been evaluated in healthy subjects. A lvelestat  
(MPH966)  is rapidly absorbed (median time to reach peak concentration 0.5 to 1.5 h), with a dose- proportional 
increase in systemic exposure.  Multiple dosing show s no clinically relevant  accumulation,  and t he PK profile was 
generally similar between healthy subjects  and patients  with lung disease . The PK data supported development  
of a model to simulate predict ed doses  and exposures for this study.  
 
Alvelestat  (MPH966)  demonstrate s dose- dependent inhibition of zymosan -stimulated neutrophil elastase activ ity 
in clinical studies36. Although at plasma alvelestat ( MPH966 ) concentrations  of >100 nM, neutrophil elastase 
inhibition was differentiated from that obs erved on placebo, plasma concentrations >300 nM, were required to 
give meaningful effects achieving a mean neutrophil elastase inhibition of 92%.  Through observed and modelled 
PK, 120 mg bid is anticipated to provide a sufficient range of plasma exposures to achieve neutrophil elastase  
inhibition  through PK levels  >300 nM  and will enable the concentration- effect relationship of alvelestat  (MPH966)  
to be characteri zed.  
 
As summarized below, the preclinical toxicology studies provide adequate safety margins for progressing to the 120 mg bid dose for 12 weeks in this study. The clinical safety experience with alvelestat to date has shown no 
signals that prevent progression of the proposed dose. The potential concern around transaminase elevation is 
considered monitorable and reversible. The safety of patients will be managed through the exclusion and 
inclusion criteria and safety monitoring approach taking into account the preclinical tox icology data and clinical 
safety information.  
 
 Protocol Version 1.4  
 
 Page 13 of 59 5.6. Preclinical Safety Studies 
 
The safety margins for alvelestat (MPH966) have been evaluated in preclinical toxicology studies  of up to 6 
months in rats, 12 months in dogs , and 3 months in mice.  
   
In rats , the no adverse effect level ( NOAE L) was 370 mg/kg/day  (1 month gavage) and 500 mg/kg/day  (dietar y 
1 to 6 month studies). These were the highest doses studied , and no toxicity was observed.  
 
In dog, 1-, 3-, and 12- month  toxicology studies at doses of 1.2, 12,  and 122 mg/kg  showed limited effect at the 
intermediate and high doses, including small decreases in bod y weight, small increases in plasma creatinine 
and trigl ycerides , and minor effects on electrocardiogram ( ECG ) with a transient increase of the QTc by Van de 
Water’s correction formula ( QTcV) (<10%). The NOAEL was considered to be 122 mg/kg. In telemetered dogs  
at doses of  50 mg/kg (corresponding to a peak plasma concentration of 39.9 µM) , a mean increase of 9% 
(individual increases of 8 % to 14%) in QTcV was seen.  
 In mice, alvelestat  (MPH966)  was well tolerated at doses up to 2000 mg/kg. Histopathology  indicated slight focal 
hepatic necrosis above control. Additional effects in liver included minor increase in glycogen vacuolation at 
2000 mg/kg , slight h ypertrophy in males at 1000 mg/kg , and increased incidence above control of inflammatory  
foci in females at 1000 mg/kg. A  recovery  group  indicated possible reversibilit y, although the interpretation was 
difficult due to the low -grade change . Overall, focal necrosis is regarded as a non -specific response in mice, with 
no signs of progression or persistence and the relevance for humans is likely  to be limited.  
 
Preclinical toxicology findings, with the exception of QTc change, would be expected to be driven by area under 
the curve ( AUC) . Based on preclinical data, a human exposure limit corresponding to the AUC at the NOAEL 
(500 mg/kg) in the rat 6 -month  study (f ree AUC of 14.7 µM.h, corresponding to a total human AUC of 25.8 µM.h) 
is considered as acceptable in clinical studies. Significant ly higher exposure levels have been evaluated in dogs 
for 12 months without an y adverse effects.   
 
The 120 mg bid dose in man is predicted to give an AUC  of 11791 nM.h,  approximately 53.8 -fold lower than that 
at the NOAEL in the 12- month study in dogs and 21.5- fold lower than NOAEL in the 6 month study in rats. The 
AUC is predicted to be approximately 9- fold below the level where liver findings in mice (increase in background 
pathology of likely limited relevance to man) were seen.  
    An additional consideration when calculating the safety margins in man compared to toxicology studies is the 
differences in plasma  protein binding seen across the species. Alvelestat (MPH966) plasma protein binding is 
less in humans than the other species investigated.  For more detailed information on the toxicology and 
nonclinical safety studies conducted to date,  please refer to the Investigator ’s Brochure.  
 
5.7. Clinical Safety Studies  
 
Clinical experience comes from 12 c ompleted  healthy volunteer and patient studies  in which 114 9 subjects have 
received at least 1 dose of alvelestat  (MPH966) . The highest single dose that has been given is 150 mg and the 
highest repeat dose is 240  mg bid (for 6 months ). In clinical studies, 540 COPD patients have received 60 mg 
bid for 3 months and 22  patients with bronchiectasis and 26 patients with cystic fi brosis have received 60 mg bid 
for 28 days. Completed clinical studies to date have not revealed an y adverse effects  on blood pressure, ECG, 
hematology , or urinal ysis that could be linke d to any of the observations in toxicology studies. For clinical 
chemistr y, there has been 1 patient with bronchiectasis with an instance of transient raised transaminases and 
1 patient with cystic fibrosis with an increase in creatine kinase, alanine aminotransferase ( ALT), aspartate 
aminotransferase ( AST), and lactate dehydrogenase. In the studies in COPD patients , there were 14 instances 
where patients experienced raised ALT or AST to ≥3 × upper limit of normal ( ULN)  across the studied doses 
(alvelestat  [MPH966]  5, 20 , and 60 mg bid). Although definit ive evidence of dose relationship was lacking, there 
was a suggestion of an increased incidence of liver transaminase elevations in patients on alvelestat  (MPH966)  
for which there were no definitive alternative explanations . The highest transaminase elevations occurred in the 
 Protocol Version 1.4  
 
 Page 14 of 59 highest alvelestat  (MPH966)  dose (60 mg  bid). There have been no cases of Hy’s law related to alvelestat 
(MPH966) treatment  reported in any of the studies to date (including up to 240 mg bid). The liver abnormalities 
noted to date with alvelestat, including from study MPH966 -2-01 have been infrequent (only 5 liver -related 
adverse events  have been reported and no SAE/ AESI of liver abnormalities have been reported in study 
MPH966- 2-01) and rarely abov e 3x ULN. Furthermore, all abnormal liver changes that have been observed have 
been reversible either with or without study drug interruption.   
 
Alvelestat  (MPH966)  is currently being administered in 3  ongoing clinical studies.  In a study in patients with 
bronchiol itis obliterans syndrome associated with chronic graft versus host disease following allogenic 
hematopoietic stem cell transplantation ([STUDY_ID_REMOVED]) , doses of up to 240 mg bid are being given. To date,  7 
patients have received 240 mg bid dose for up to 6 months . One patient underwent dose reduction to 180 mg  
bid following a SAE of severe gastroenteritis and renal failure that was considered unrelated to alvelestat 
(MPH966). A second patient had elevation of transaminases with temporary treatment discontinuation on a dose 
of 60 mg bid. The event was considered related to alvelestat (MPH966) , and drug was restarted at the dose of 
60 mg bid at recovery f ollowing a 2 -week temporary discontinuation.  In an ongoing blinded study in AATD -related  
lung disease (MPH966- 2-01, [STUDY_ID_REMOVED]) 50 participants have been randomized to dat e to alvelestat (either 
120 mg bid, 240 mg bid) or placebo (1:1:1)  for 12 weeks duration, no safety signals have been identified.  
 
For more detailed information on clinical safety studies conducted to date , please see additional details below 
and also refer to the current  Investigator ’s Brochure.  
 
5.8. Benefit -Risk Assessment  
 
Patients with AATD -related lung disease present at a younger age and show more rapid progression that non -
AATD COPD.  The most common symptoms are shortness of breath, wheeze, chronic cough , and sputum 
production with a propensity for recurrent respiratory infections and bronchiectasis.  Available therapies  consist 
of chronic symptomatic treatment for COPD  with bronchodilators and inhaled corticosteroids as well as 
management  of acute exacerbations. None of these affect the progressive decline in lung function that may lead 
to severe structural damage, loss of lung function,  and the need for lung volume reduction or transplantation in 
a select group. Augmentation with AAT protein is used in severe cases, with some evidence for effect  on 
progression of lung damage. However , the costs of administration and the inconvenience for patients of a weekly 
intravenous therapy mean t here is a high unmet need for more effective and convenient therapy.   
 
Alvelestat  (MPH966) is  a potent, selective , and reversible inhibitor of human neutrophil elastase. E fficacy has 
been demonstrated in in vivo  models of lung inflammation and elastase -induced lung injury32. Across clinical 
studies in COPD, cystic fibrosis , and bronchiectasis , there has been some evidence for  effects on elastin 
breakdown, inflammatory biomarkers , and lung function. The extent of these effects was not consistent in all 
studies. This may be due to the heterogeneity of the pathogenesis and/or the doses used (maximum 60 mg bid) that would not be expected to adequately inhibit neutrophil elastase, allowing inflammatory “escape” . Greater 
efficacy and clinical benefit is expected by targeting patients with AATD -related lung disease,  in which neutrophil 
elastase is considered the key pathogenic driver , and by using a dose of alvelestat (MPH966) to maintain 
neutrophil elastase  inhibition throughout the 24- hour period.  
 
Alvelestat (MPH966) has been previously evaluated in clinical studies of up to 12 weeks in duration as a potential 
novel oral treatment to control the symptoms and exacerbations of COPD and reduce the progression and 
severity of the disease. Alvelestat (MPH966) has also been evaluated in studies in 2 other airway diseases 
character ized by neutrophilic inflammation: bronchiectasis
37 and cystic fibrosis35. Both studies were of 28 days 
in duration.  
 Headache was the most frequently reported AE in 8 of the 12 completed studies to date. In healthy volunteer 
studies, headache was reported more commonly in  the avelestat ( MPH966)  group than the placebo group. 
Headache was generally mild in intensity ( although 1 subject had severe headache),  and there was no evidence 
of a dose– related relationship. In studies wit h cystic fibrosis and bronchiectasis, headache was also generally 
 Protocol Version 1.4  
 
 Page 15 of 59 reported more commonly in the alvelestat (MPH966) group compared to placebo. In the BREEZE 
(D0520C00012) and MISTRAL (D0520C00020) COPD studies, headache remained one  of the most common 
AEs reported and was the most commonly reported treatment -related AEs (3 patients in the alvelestat [ MPH966]  
60 mg group) in the MISTRAL study . Headache has also been the most frequently reported adverse event 
particularly in the 240 mg bid dose group in study MHP966- 2-01. 
 
In the Phase 2b COPD program , there were 14 reported events of raised ALT or AST to ≥3 × ULN across the 
studied doses (alvelestat [ MPH966] ) 5, 20,  and 60 mg bid); there were no cases of Hy’s law during the treatment 
period. Although definitive evidence of dose relationship was lacking, there was a suggestion of an increased 
incidence of liver transaminase elevations in patients on alvelestat (MPH966) for which there were no definitive 
alternative explanations. The highest transaminase elevations occurred in the highest alvelestat (MPH966) dose (60 mg bid). Elevations in hepatic biochemistry ass essments (transaminases) observed in patients in the 
alvelestat (MPH966) studies were confounded by alcohol  or by  concomitant medication, but an effect of 
alvelestat (MPH966) cannot be excluded at this time . A significant proportion (49 %) of adult patients with Pi*ZZ 
AATD  have been shown to have small increases in levels of ALT
41 and some develop cirrhosis. It is therefore 
possible that patients with AATD may be more susceptible to liver function AEs . Therefore,  exclusion criteria for 
clinically relevant hepatic fibrosis , in-study monitoring,  and study treatment  discontinuation criteria are in place 
to prot ect the safety of the subjects and liver abnormalities are included as adverse events of special interest 
(AESI ). 
 
There were no other clinically relevant changes in clinical chemistry data in the completed studies with alvelestat 
(MPH966). There were also no clinically relevant changes in urinalysis were observed in the completed studies 
with alvelestat (MPH966). There were no changes in ECG or vital signs data that indicated a clear treatment 
effect of alvelestat (MPH966).  However , in light of the minor changes in QTc in the dog toxicology, exclusion  
criteria and regular ECG monitoring at the time of peak concentrations of study treatment  and discontinuation 
criteria will be applied in the study. Clinically significant changes in ECG are also included as an AESI.  
 
Mutations in ELAINE, the gene that encodes neutrophil elastase, are associated with cyclical neutropenia , 
severe congeni tal neutropenia, and susceptibility to  recurrent  infection. To date,  no increases in rate or severity 
of infection or  neutropenia have been reported with alvelestat. However, for this initial study in AATD , patients 
with neutropenia will be excluded, new onset of neutropenia will constitute a patient stopping criterion,  and 
infections will be an AESI  to monitor the safety profile as higher doses are explored in a new population.  
 
There have been no liver abnormalities in the current study , and those noted to date with alvelestat in study 
MPH966- 2-01, also in alpha- 1 antitrypsin deficiency , have also been infrequent (only 5 liver -related adverse 
events  have been reported and no SAE/ AESI) and rarely above 3x ULN. Furthermore, all abnormal liver changes 
that have been observed have been reversible either with or without study drug interruption up to doses of 240 
mg bid for 12 weeks . 
 
At present, based on the cumulative review of the data and with no new safety issues seen in the ongoing studies 
with dosing up to 240 mg bid of alvelestat  (MPH966) , the safety profile of alvelestat  (MPH966 ) remains 
unchanged and the benefit -risk balance continues to support the clinical development of alvelestat (MPH966). 
The potential or theoretical safety concerns on liver function, QTc changes , and susceptibility to infection are 
manageable through exclusion criteria, monitoring, study treatment  discontinuation criteria , and independent 
safety review through the DSMB , as detail ed in Appendix 7.   
 
More detailed information about the known and expected benefits  and risks and reasonably expected AEs  of 
alvelestat  (MPH966 ) may be found in the current version of the a lvelestat (MPH966) Investigator’s Brochure.  
P rotocol Version 1.4 
P age 16 of 59 6. Study Population
P
rospective approval of protocol dev iations to recruitment and enrolment criteria, also known as protocol waivers 
or exemptions, are  not permitted.  
6.
1. Inclusion Criteria  
Participants are eligible to be included in the study only if ALL  of the following criteria apply:  
T
ype of Participant and Disease Characteristics 
1.Capable of giving signed informed consent as  described in Appendix 3, which includes c ompliance with the  
requirements and restrictions l isted i n the informed consent form and i n this pr otocol
2.Ag
e ≥18 and ≤ 80 years
3.Patients with a confirmed diagnosis of AATD : Pi*ZZ, Pi*SZ, Pi*null, or another rare phenotype/genoty pe
k
nown to be associated with either  low (serum AAT level <11 μM or <57.2 mg/dL) or functionally impair ed
A
AT including “ F” or “I” mutations .
4.FEV1 ≥25% pred icted
5.Patients will be eligible if they are either a) are not currently receiving augmentation treatment and have not
received augmentation in the 12 weeks prior to screening or b) have received weekly infusions of
augmentation at 60 mg/kg for at least 12 weeks prior to screening and intend to continue augmentationthrough the study period.
6.Male or female sex
a.
Male participants  must agree to use a highly effective contraception as detailed in Appendix  5 during  
the treatment period and for at least 4 days after the last dose of study treatment and refrain from 
donating sperm during this period
b.Fem
ale participants are eligible to participate if not pregnant; not breastfeeding; and at least one of
the following conditions is met:
i.Not a woman of childbearing potential as defined in Appendix  5
OR 
ii.A
 woman of childbearing potential who agrees to follow the contraceptive guidance in
Appendix 5. During the treatment phase and for at least 4 days after the last dose of study 
medication.  
6.
2. Exclusion Criteria  
Participants are excluded from the study if ANY  of the following criteria apply:  
E
xcluded Medical Conditions  
1. S
ubjects with Pi* MZ, Pi *FM, Pi*MS, Pi*SS,  or other AATD phenotypes/genotypes  not known to be
independently associated with emphysema.
2.A
ny clinically diagnosed lung disease other than COPD such as diffuse interstitial lung diseases, cystic
fibrosis, or clinically significant bronchiectasis as determined by the Investigator
3.Acute exacerbation of underlying lung disease requiring oral steroids and/or antibiotics within 4 weeks ofbaseline
4.Acute or chronic hepatitis, including hepatitis B, hepatitis C (positive serologies, including hepatitis B and Cantibody)
5.HIV infection or other im munodeficiency or with an absolute neutrophil count ≤1.0 × 10
9/L
6.Abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma- glutamyl
transferase) >1.5 × upper limit of normal or total bilirubin > upper limit of normal (unless Gilbert’s disease
with normal conjugated bilirubin)
 Protocol Version 1.4  
 
 Page 17 of 59 7. Any of the following laboratory abnormalities are present at baseline:  
a. Platelet count <150×109/L 
b. Serum albumin ≤ 3. 5 g/dL 
c. INR ≥1.2  
d. CPK ≥ ULN.  
8. History or current evidence of cirrhosis (on biopsy or imaging), esophageal varices, ascites or hepatic 
encephalopathy.  
9. Evidence of other forms of chronic liver disease based on diagnostic testing as per the guidelines (i.e. 
autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, W ilson’s disease, 
Hem ochromatosis or iron overload).  
10. Patients with nonalcoholic fatty liver disease (NAFLD)  as diagnosed by any imaging modality  (or use of 
drugs associated with NAFLD for more than 2 weeks in the year prior to screening) .  
11. Subjects with a history of significant alcohol consumption for a period of more than 3 consecutive months 
within 1 year prior to screening, defined as average of >20g/ day in female subjects and >30g/ day in male 
subjects.  
12. Fibrosis -4 (FIB-4) score >3.25  
13. Any of the followi ng cardiovascular conditions within 6 months prior to the screening visit:  
a. Myocardial infarction or unstable angina  
b. Coronary artery bypass surgery, balloon angioplasty, percutaneous coronary intervention, or carotid 
revascularization procedure  
c. Uncontrolled hypertension  
d. Stroke or transient ischemic attack  
14. Congestive heart failure (New York Heart Association III/IV) with left ventricular ejection fraction < 40%  
15. Any clinically significant 12 -lead electrocardiogram abnormalities at screening or baseline, incl uding 
corrected QT interval by Fridericia’s correction method >450 ms or history of significant cardiac dysrhythmia, 
including long QT syndrome  
16. History of cancer within the last 5 years, except for well -treated basal cell carcinoma and s quamous cell 
carcin oma of the skin  
17. Other documented comorbidities or laboratory abnormalities that in the opinion of the Investigator could affect the outcome of the study assessments, participant safety, or ability of the participant to comply with the 
requirements of the protocol  
 Excluded Prior/Concomitant Therapy  
 
18. Daily use of prednisone (>10mg daily), or other systemic glucocorticoids at comparable or higher equivalent 
dose, or use of other immunosuppressant therapies are prohibited  
19. Immunomodulating monoclonal antibodies within 6 months prior to screening are prohibited  
20. Daily use of non- steroidal anti -inflammatory drugs (NSAIDs) is prohibited.  Daily use of acetaminophen up 
to 2 g per day and aspirin up to 325 mg per day is permitted.  
21. Initiation of drugs known for hepatotoxic potential within the 28 days prior to s creening including but not 
limited to: statins, NSAIDS, amoxicillin/clavulanate, PDE inhibitors (theophylline, roflumilast), and anti -
epileptics.  Subjects on established treatment for more than 28 days prior to screening will not be excluded.  
Requirement for medications mainly metabolized by CYP2C9 and with narrow therapeutic index (eg, 
warfarin , phenytoin)  is prohibited 
 Excluded Prior/Concurrent Clinical Study Experience  
 22. Participation in any clinical investigation using medical devices or non- biologic t reatments within 4 weeks or 
5 half -lives of the drug (whichever is longer) prior to the initial dosing (or longer if required by local regulations)  
is prohibited  
23. Participation in any clinical investigation using biologic treatment within 6 months of screening is prohibited 
24. Previous participation in a gene therapy study for AATD at any time is prohibited 
 Protocol Version 1.4  
 
 Page 18 of 59 Other Exclusions  
 
25. History of hypersensitivity to alvelestat (MPH966) or any of its excipients or the class of neutrophil elastase 
inhibitors  
26. Known hy persensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine 
for bronchoscopy)  
 
6.3. Lifestyle Restrictions  
 
6.3.1.  Meals and Dietary Restrictions  
 
There are no specific restrictions in respect of mealtimes and administration of study treatment . 
 6.3.2.  Alcohol and Tobacco  
 
Tobacco cessation is encouraged but is not required for the study  duration . 
 
Participants should avoid alcohol during the 12 week active study period.  
 6.3.3.  Activity  
 
Subjects should not participate in unaccustomed or more vigorous exercise than usual routine in the 48 hours 
before each blood sample for laboratory safety tests.  
 
6.4. Screen Failures  
 Screen failures are defined as participants who consent to participate in the clinical study but are not 
subsequently random ized. A minimal set of screen failure information is required to ensure transparent reporting 
of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, available eligibility criteria, and any SAE s.  Individuals who do not meet the criter ia for 
participation in this study (screen failures) may be rescreened  after discussion with and approval by the Data 
Coordinating Center  (DCC)  and/or Principal  Investigator  (PI).  
 The screening period may be extended beyond 28 days in the following circu mstances after discussion with 
and approval of the DCC and/or PI: 
 
• All screening inclusion/exclusion criteria are met but the participant ’s schedule, including genetic testing, 
prevented random ization  within the screening period.  
• The participant experiences an acute exacerbation of COPD  during the screening period.  
 Additionally , individual lab oratory  parameters or screening test s may be repeated, within the screening period,  if 
the result is considered aberrant or not clinically consistent with the patient’s health status. Decisions to re- test 
should be made in conjunction with the study PI . 
 
Particip ants who have individual laboratory parameters re -tested  should have the results entered in the electronic 
case report form  (eCRF ).  
 Protocol Version 1.4  
 
 Page 19 of 59 7. Treatment s 
 
Study treatment is defined as the investigational treatment  or placebo.  
 
7.1. Treatment s Administered  
 
Study Treatment Name:  Alvelestat 120 mg  Placebo  
Dosage Formulation:  Tablet  Tablet  
Unit Dose Strength(s) / 
Dosage Level(s):  4 × 30 mg Alvelestat  4 × 30 mg Placebo  
Route of Administration   Oral Oral 
Dosing Instructions:  To be taken bid, 12 hours apart and with water  
Packaging and Labeling : Study treatment will be provided in boxes . Each box  will contain 
treatment for 7 days and will be labeled as required per U.S.  
regulations . 
Manufacturer : Mereo Bio Pharma 4 Ltd. , 1 Cavendish Place, London , W1G 0QF , UK 
 
7.2. Method of Treatment Assignment  
 
All participants will be centrally random ized 1:1 to the 120 mg and placebo arms using an i nteractive web 
response system (IWRS).  A unique number will be assigned to each participant and will be linked  to 
randomi zation numbers  using a randomi zation list produced by the DCC. These randomi zation numbers will be 
linked to the 2 treatment regimens , and the randomi zation scheme will be stratified according to genotype (Pi*ZZ, 
Pi*SZ, Pi*(Null) (Null) ) and clinical center . 
 
7.3. Blinding   
 
This is double- blind study. The investigator s, participants , Mereo and NCATS  will remain blinded to the study 
treatment allocation until the end of the study. The randomi zation list will be kept secure from the study team, 
investigators , and participants throughout the conduct of the study and until unblinding is author ized by the DCC. 
The DSMB  will be unblinded according to the DSMB  charter.  
 
The IWRS will be programmed with blind- breaking instructions. The study blind may be broken for a medical 
emergency in which the knowledge of the specific blinded study treatment will affect the immediate management 
of the participant’s condition. In this case, the DCC , the NCATS Medical Monitor,  and Mereo must be notified 
within 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation and case report form ( CRF), as applicable.  
 
 Protocol Version 1.4 
 
 Page 20 of 59 7.4. Preparation/Handling/Storage/Accountability  
 
Only partic ipant s enrolled in the study may receive study treatment, and only author ized site staff may supply or 
administer study treatment.  All study treatments must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labelled storage conditions with access limited to 
the Investigator  and author ized site staff . 
 The Investigator , institution, or the head of the medical institution (where applicable) is responsible for study 
treatment accountability, reconciliation, and record maintenance (i .e., receipt, reconciliation, and final disposition 
records) . 
 
Further guidance and information for the final disposition of unused study treatment are provided in the Manual 
of Procedures (MOP) .  
 
7.5. Treatment Compliance   
 The per -protocol dosage, timing, and mode of administration of study treatment may not be changed. Any 
departures from the intended regimen must be recorded in the electronic eCRF and reported to the DCC. 
 7.6. Concomitant Therapy  
 Treatment for Respiratory Disease  
 
Bronchodilators are allowed as prescribed. H owever , they should be withheld for the required time before 
spirometry as detailed in the MOP . 
 
Other regular medications for treatment of airways disease (e.g., inhaled bronchodilators or inhaled 
corticosteroids)  are permitted provided the subject has been on a stable dose for 1 month before baseline.  
 Systemic Corticosteroids 
 
Regular systemic steroids are not permitted during the study, unless clinically indicated to treat acute 
exacerbation . 
 
Vaccines 
 
Patients should be vaccinated against pneumococcus and receive annual influenza vaccination.  
 
CYP2C9 Substrates  
 MPH966 has a weak potential to inhibit CYP2C9. Therefore,  medications that are metabol ized mainly by 
CYP2C9 and have a narrow therapeutic index are prohibited. Narrow therapeutic index CYP2C9 substrates include warfarin and phenytoin ( a complete list is included in the MOP  or online at 
http://medicine.iupui.edu/clinpharm/ddis/main- table/ ). 
 Enhanced clinical monitoring in patients receiving sensitive/moderate sensitive CYP2C9 for enhanced clinical 
effect should be considered. Moderate sensitive substrates include tolbutamide and glimepiride. 
 Therapies Known to Cause Liver Function Abnormalities  
 
Daily treatment with acetaminophen at doses greater than 2 g per day or non- steroidal anti -inflammatory drugs  
(NSAIDs) is  not permitted during the study. Acetaminophen at doses of up to 2 g per day and aspirin up to 325 
mg per day are  permitted during the study.  
 Protocol Version 1.4  
 
 Page 21 of 59  
Initiation of drugs known for hepatotoxic potential within the 28 days prior to screening including but not limited 
to: statins, amoxicillin/clavulanate, PDE inhibitors (theophylline, roflumilast), and anti -epileptics is exclusionary.  
Subjects on established treatment for more than 28 days prior to screening will not be excluded.  
 During the course of the study , if medications are required,  a concomitant medication’ s hepatotoxicity and 
alternative treatments, if possible , should be considered. In the event that no alternatives are available and the 
medication is required to treat  the medical condition,  the Inves tigator should discuss the subjects ’ ongoing 
participation in the trial with the study PI  and/or DCC  at the earliest possible opportunity.   
 Any medication or vaccine (including over -the-counter or prescription medicines, vitamins , and/or herbal 
supplements) that the participant  is receiving at the time of enrolment  or receives during the study must be 
recorded along with:  
 
• Reason for use 
• Dates of administration including start and end dates  
• Dosage informati on including dose and frequency  
 
The DCC and/or study PI  should be contacted if there are any questions regarding concomitant or prior therapy.  
 7.7. Treatment After the End of the Study  
 
Alvelestat (MPH966)  will not be provided after  the end of the study.  
 Protocol Version 1.4  
 
 Page 22 of 59 8. Discontinuation Criteria  
 
8.1. Discontinuation of Study Treatment   
 
In considering discontinuation of the study treatment, the Investigator should give particular consideration of the 
following:  
 Liver Test Abnormalities 
 
The following monitoring schedule is proposed when a case of acute liver function abnormalities or worsening of a liver function abnormality is reported:  
 
• If ALT or AST are between 1.5  to 3 × ULN, regular monitoring (every 2 weeks at a minimum) is required 
until event resolution and patient can continue on study treatment  during this period . 
 
• If ALT or AST are ≥3 × ULN, repeat the test within 48 to 72 hours and the study treatment  will be 
temporarily discontinued while  awaiting repeat tests results; if the repeat tests is again ≥3  × ULN or 
≥2 × pre-treatment level, testing needs to be repeated at least twice weekly until event resolution or a 
return to baseline value while the study treatment  is withheld .  
 
• If AST or ALT are ≥5x ULN, a repeat value should be obtained within 24 -48 hours. If the repeat ALT 
and AST values is ≥5 x ULN, the drug should be discontinued and the patient followed until the 
laboratory values normalize or stabilize, in addition to initiating potential (Drug Induced Liver Injury) DILI 
evaluation.  
 Discontinue Alvelestat (MPH966) for the following hepatic adverse events:  
 
• Regardless of the magnitude of the transaminase elevation, if the bilirubin is  elevated (any level) in 
addition to the presence of signs and symptom(s) such as  rash, eosinophilia, nausea, vomiting, or right 
upper quadrant pain,  
 
• INR ≥1.5 and TB ≥2x ULN, irrespective of the magnitude of ALT or AST  elevation.   
 
• TB elevation ≥2x ULN, and ALP ≥2x ULN for cholestatic liver injury.  
 
For each scenario, initiate potential DILI evaluation for alternative etiologies and obtain a hepatology consult. Liver biopsy should be considered for DILI. The complete liver profile including PT/INR must be 
repeated within 48 -72 hours after first abnorm al value is obtained. Follow the patient until laboratory 
parameters stabilize or normalize. Study medication can be restarted only if an alternative etiology is “definitively” identified and liver tests have returned to baseline.  Testing for alternative etiologies can 
include serology tests (hepatitis A, hepatitis B, hepatitis C, Cytomegalovirus ( CMV ), Epstein- Barr Virus 
(EBV) , Herpes Simplex Virus (HSV) , varicella  zoster virus (VZV) , parvovirus, toxoplasmosis), imaging, and 
pathology assessments ( creatine phosphokinase, clotting)  as appropriate to the clinical situation.  
 
Clinically significant liver function abnormalities should be reported as an AE/AESI . 
  
 Protocol Version 1.4  
 
 Page 23 of 59 When the following abnormal liver test conditions are met , study treatment MUST  be discontinued,  the DCC and 
study PI informed,  and further steps discussed:  
 
• ALT/AST >5  × ULN on 2 consecutive tests  within 24 to 48 hours OR 
 
• ALT or AST >3  × ULN and total bilirubin >2 × ULN OR 
 
• ALT or AST >3  × ULN and  international normal ized ratio (INR) >1.5 OR  
 
• ALT or AST >3  × ULN the appearance of worsening fatigue, nausea, vomiting, right upper quadrant 
pain/tenderness, fever, rash,  or eosinophilia 
 
ECG  Abnormalities  
 
If a clinically significant finding is identified (including but not limited to changes from baseline in QTcF  after 
enrolment ), the Investigator  or qualified designee will determine if the participant can continue in the study and 
if any change in participant management is needed. This review of the ECG printed at the time of collection must 
be documented. Any new clinically relevant findi ng shoul d be reported as an AE.  
 
When the following ECG change conditions are met, study treatment MUST  be discontinued,  the DCC and study 
PI informed , and further steps discussed:  
 
• Absolute QTcF >500 ms or >60 ms increase from baseline as confirmed with 3 consecutive ECG s taken 
in a 30 -minute period with at least 5 minute s between each ECG. The mean of the 3 ECGs will be used 
for decision making.  
 
Other Laboratory Parameters  
 
Study treatment MUST  be discontinued if the following laboratory parameters criteria are met:  
 
• Absolute neutrophil count less than or equal to 1.0 x 109/L on 2 consecutive repeat tests  within 48 to 72 
hours.  
 
Other  
 Study treatment MUST  be discontinued if the following other criteria are met:  
 
• Significant safety issues (as judged by the Site Investigator). This includes AEs considered unacceptable 
by the patient and/or the Investigator  
• Any other protocol deviation that results in a significant risk to subject’s safety  
 
• Pregnancy as confirmed by positive urine test at any time during the study  
 
• Withdrawal of informed consent  
 Participants  may volunt arily discontinue investigational treatment for any reason at any time. Participant  decision 
on discontinua tion of study treatment  does not imply an automatic withd rawal from the study.  
 
Refer to the Schedule of Activities ( SoA)  for data to be collected at the time of treatment discontinuation and 
follow- up and for any further evaluations that need to be completed . 
 
P rotocol Version 1.4 
P age 24 of 59 8.1.1.  Temporary Discontinuation   
S
tudy treatment  dosing may be temporarily suspended in the event of:  
•Clin
ically import ant laboratory abnormalities
•O
ther intercurrent illnesses  including acute exacerbations of COPD , major surgery , or gastrointestinal
problems
•U
se of prohibited treatment
•A
ny other protocol deviation that results in a significant risk to the participant’s safety
A
fter a laboratory abnormality leading to a delay of dosing normali zes sufficiently, study treatment may resume 
at the discretion of the Site I nvestigator  in consultation with the Study PI as needed. Similarly, study treatment 
may resume after the medication leading to suspension of dosing is discontinued. A decision to discontinue 
study treatment  and/or to reinstitute study treatment should be conveyed to the Study PI and the DCC. The 
Investigator  may suspend study treatment at any time, without consultation with the Study PI if the urgency of 
the situation requires immediate action and if this is determined to be in the participant’s best interest. However, the Study PI and DCC should be contacted as soon as possible in any case of study treatment  discontinuation. 
8.
1.2. Re-challenge  
R
esumption of study treatment after temporary discontinuation should always be discussed with the DCC and 
study PI . 
Re-challenge should be performed one time only  if the study medication was held due to AST or ALT ≥3x ULN. 
Re-challenge should only occur  after the ALT or AST return to pretreatment baseline value.  
In the specific case of liver tests meeting the study treatment dis continuation c riteria in Section 8.1, no re-
challenge is per mitted. 
8.
2. Discontinuation  From the Study  
The 
Investigator should consider the following when withdrawing a participant from the study:  
•A
 participant may withdraw from the study at any time at his/her own request, or may be withdrawn at
any time at the discretion of the Investigator  for safety, behavioral, or administrative reasons.
•If
 the participant  withdraws consent  for disclos ure of future information, the DCC may retain and conti nue
t
o use any data collected before such the withdrawal of consent .
•I
f a participant  withdraws from the study, he/she may request destruction of any samples taken and not
tested , and the Investigator  must document this in the site study records  and notify the DCC.
8.
3. Lost to Follow -up 
A par
ticipant  will be considered lost to follow- up if he /she repeatedly fails to return for scheduled visits and is 
unable to be contacted by the study site.   
 Protocol Version 1.4  
 
 Page 25 of 59 The following actions must be taken if  a participant  fails to return to the clinic for a required study visit:  
 
• The site must attempt to contact the participant  and reschedule the m issed visit as soon as possible and 
counsel the participant  on the importance of maintaining the assigned visit schedule and ascertain 
whether or not the participant  wishes to and/or should continue in the study.  
 
• In cases in which the participant  is deemed lost to follow -up, the Investigator  or designee must make 
every effort to regain contact with the participant  (where possible, 3 telephone calls and mail a certified 
letter to the participant ’s last known mailing address. These contact attempts should be documented in 
the participant ’s file. 
 
• Should the participant  continue to be unreachable, he/she will be consi dered to have withdrawn from the 
study with a primary reason of lost to f ollow- up.  
 
9. Study Assessments and Procedures  
 
• Study procedures and their timing are summar ized in the S OA.  
 
• Adherence to the study design requirements, including those specified in the S OA, is essential and 
required for study conduct.  
 
• All screening evaluations must be completed and reviewed to confirm that  potential participant s meet all 
eligibility criteria. The Investigator  will maintain a screening log to record details of all participant s 
screened and to confirm eligibility or record reasons for screening failure, as applicable.  
 
• . 
 
• Sample handling: Routine bloodwork and laboratory measurements used for safety monitoring and 
eligibility assessment (CMP, coagulation measurements, CBC, pregnancy testing, etc. ) will be processed 
and measured using local laboratory.  Samples (blood, sputu m, BAL) used for PK or biomarker 
assessment will undergo initial processing at the local site but will be shipped to a central lab (Dr. Wells) 
at UAB for curation and analysis.  The procedure is detailed in the MOP.  
 
• Repeat or unscheduled samples may be ta ken for safety reasons or for technical issues with the samples . 
 
• Biomarker  samples (blood, sputum , and BAL ) will be stored for up to 60 months after the end o f the study . 
 
P rotocol Version 1.4 
P age 26 of 59 9.1. Key Screening Assessments  
FIB-4 S
core 
The FI
B-4 test combines age with 3 standard biochemical values (platelets, ALT, and AST) as a non- invasive 
test to assess fibrosis and enable exclusion of participants who may be at greater risk of liver AEs 
(https://www.mdcalc.com/fibrosis -4-fib-4-index -liver-fibrosis ). The following formula will be used:  
U
sing a cut -off value of 1.45, a FIB -4 score <1.45 has been shown to have a negative predictive value of 90% 
for advanced fibrosis.  In contrast, a FIB -4 >3.25 would have a 97% specificity and a positive predictive value of 
65% for advanced fibrosis42. FIB-4 index has been shown to be superior to other scoring systems for 
differentiating between advanced and mild fibrosis .   
9.
2. Efficacy Assessments  
9.
2.1. Blood, Sputum , and Bronchoalveolar Lavage  Biomarkers  
B
lood 
B
lood will be collected as per the SOA, and samples will be collected and processed as described by the MOP . 
S
putum  
S
putum will be collected from induced samples  (refer to the MOP  for processing details).   Sputum induction will 
not be undertaken if the baseline FEV 1 for the procedure is less than 1 L. Further details of sputum induction will 
be included in the MOP .  Sputum induction is considered an aerosol generating procedure (AGP) and sites 
should use local guidance on conducting AGP as part of clinical research in the COVID -19 era.  
B
ronchoalveolar Lavage (BAL) 
B
AL will be collected in the subset of participants who agree to participate in the bronchoscopy sub -study.  
Samples will be collected at two time points as per the SOA, and samples will be collected and processed as 
described by the MOP .  Bronchoscopy and BAL is considered an aerosol generating procedure (AGP) and sites 
should use local guidance on conducting AGP as part of clinical research in the COVID -19 era.  
Blood, sputum, and BAL efficacy biomarkers (se e Table below) will be taken at the time points as detailed in 
the SoA to evaluate their association with the obs erved mechanism of action responses to neutrophil 
elastase inhibition, including response of neutrophil elastase activity, inflammation, and lung damage to 
alvelestat (MPH966). 
The s
amples will be collected and processed as described in the MOP . 

 Protocol Version 1.4  
 
 Page 27 of 59  
Samples may be stored for a maximum of 60 months  following the end of study at a facility selected by the 
Sponsor  to enable further analysis of biomarker responses to alvelestat (MPH966) .  
 
Biomarkers of Efficacy Collected in B lood and Sputum  
 
Biomarker  Blood  Sputum  BAL 
Neutrophil Elastase Related Biomarkers   
Desmosine/Isodesmosine  X X X 
Aα-Val360 X X X 
NE X X X 
EL-NE X X X 
Proteinase 3  X  X 
Cathepsin B  X  X 
Lung Damage Biomarkers  
EL-CG X  X 
EL-P3 X  X 
PGP  X X X 
C6M  X  X 
C1M  X  X 
PRO -C6 X  X 
Inflammatory Biomarkers  
Hs-CRP  X   
IL-6  X X X 
IL-8 X X X 
RANTES  X X  
IL-1β X X  
Fibrinogen  X   
LTB-4  X X 
MMPs  X X X 
MPO  X X X 
 
In addition, samples will be stored and analysis may be performed on additional  biomarker variants thought to 
play a role in neutrophil elastase– induced lung damage to evaluate their association with observed neutrophil 
activation responses to alvelestat (MPH966).  
 9.2.2.  SGRQ -C  
 
The St. George’s Respiratory Questionnaire ( SGRQ -C) will be administered at time points as detailed in the 
SoA. This is a questionnaire that measures health impairment in patients with COPD
43. It consists of 3  parts: a 
symptom score, an activity  score,  and an impact score. A total score is also produced.  
 
9.2.3.  COPD Assessment Test (CAT)  
 The CAT is an 8 item questionnaire used to report health status in COPD
44.  It will be administered at time 
points as shown in the SOA.  
 
9.2.4.  Modified Medical Research Council (MMRC)  
 The MMRC will be administered at time points as detailed in the SoA  and is used to measure dyspnea on a 5-
point scale
45.  
 
 Protocol Version 1.4  
 
 Page 28 of 59 9.2.5.  San Diego Breath Questionnaire (SOBQ)  
 
The SOBQ assesses patient reported dyspnea46.  The SOBQ  will be administered at time points as detailed in 
the SoA.  
 
9.2.6.  Pulmonary Function Testing/Spirometry  
 
Pulmonary function testing (FEV 1, FVC, FEV 1/FVC, and maximal mid -expiratory flow) will be performed at the 
times specified in the SoA  according to ATS guidelines .  Further details on the spirometry procedure can be 
found in the Specific MOP . Spirometry is considered an aerosol generating procedure (AGP) and sites should 
use local guidance on conducting AGP as part of clinical research in the COVID -19 era.  
 9.2.7.  Daily respiratory symptom scores and peak flow by electronic diary  
 
Participants will complete a 2 week baseline period of diary entries after screening and prior to randomization to 
establish a baseline.  Participants will then complete the daily diary throughout the 16 week treatment period.  
Study sites will review diary entries at each clinic visit to confirm compliance and query possible adverse events .  
 
9.3. Safety Assessments  
 Planned time points for all safety assessments are provided in the SoA.  
 
9.3.1.  Physical Examinations  
 
• A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal,  integumentary, and neurological systems. Height and weight will also be 
measured and recorded.  
 
• A brief physical examination will include, at a minimum, assessments of the lungs, heart , abdomen, and 
skin. 
 
• Investigators should pay special attention to clinical signs related to previous serious illnesses.  
 
9.3.2.  Vital Signs  
 
Vital signs will be measured in a semi -supine position after 5 minutes  of rest and will include temperature, systolic 
and diastolic blood pressure, heart rate , respiratory rate, and pulse oximetry .  
 
• Oral or tympanic temperature . 
 
• Blood pressure and pulse measurements will be assessed with a completely automated device. Manual 
techniques will be used only if an automated device is not available.  
 
• Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the 
participant in a quiet setting without distractions (e .g., television, cell phones).  
 
• Pulse oximetry will be measured using a sensor placed on the participant’s fingertip or earlobe.  Oxygen saturation (SpO2) will be recorded.  
 
Pr otocol Version 1.4 
Pag e 29 of 59 Electrocardiograms  
•12-lead ECG will be obtained as outlined in the SoA us ing an ECG machine that automatically calculates  
the heart rate and measures  PR, QRS, QT, and QTc intervals . Refer to Section 8.1 for QTc withdrawal  
criteria and additional QTc readings that may be necessary.
•Single ECGs will be performed at all sc heduled time points, with the exception of when a change from  
baseline occurs that meets drug discontinuation criteria (Section 8.1). In this situation, a triplicate  
measurement is required to confirm the finding and for discontinuation decisions.
•When a 
triplicate ECG is required, 3 consecutive  ECG tracings should be taken in a 30- minute period
with at least 5 minutes between each ECG .
•QTc
 value will be calculated using the Fridericia formula (QTc=QT/3√RR).
9.3.
3. Clinical Safety Laboratory Assessments  
•Ref
er to Appendix 2  for the list of clinical laboratory tests to be performed and to the S OA for the timing
and frequency.
•The Inv
estigator  must review the laboratory report, document this review, and record any clinically
relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must
be filed with the source documents. Clinically significant abnormal la boratory findings are those that are
not associated with the underlying disease, unless judged by the Investigator  to be more severe than
expected for the participant's condition.
•Al
l laboratory tests with values considered clinically significantly abnormal during participation in the study
or within 28 days after the last dose of study treatment should be repeated until the values return to
normal or baseline, with a frequency based on the judgement of the Site Investigator. If such values do
not return t o normal/baseline within a period of time judged reasonable by the Investigator , the etiology
should be identified and the DCC notified.
The monitoring schedule proposed for a c ase of acute liver function abnormalities or worsening of a
liver
 function abnormality is reported is listed in Section 8.1 (Liver Test Abnormalities).
•Cl
inically significant liver function abnormalities should be reported as an AE/AESI .
•Al
l protocol -required laboratory assessments, as defined in Appendix 2, must be conducted in
accordance with the MOP  and the S OA.
9.3.
4. Data Safety Monitoring Board  
Saf
ety will be regularly reviewed by an independent DSMB  who will have the option to unblind masked group 
data as necessary .  
At any ti
me, the DSMB  may choose to recommend pausing, modifying , or stopping enrolment . 
Full 
details of composition, operation al aspects, and data to be reviewe d and recomm endations to be  made by 
the DSMB  will be  descr ibed in the DSMB  charter. 
Pr otocol Version 1.4 
Pag e 30 of 59 9.4. Adverse Events  
The de
finitions  of an AE , SAE, SUSAR, and UP can be found in Appendix  4. 
An AE will be reported by the participant  (or, when appropriate, by a caregiver, surrogate, or the participant 's 
legally author ized representative) .  
The Investigator  and any  designees are responsible for detecting, documenting, and reporting events that meet 
the definition of an AE or SAE and remain responsible for following AEs that are serious, considered related to 
the study treatment or the study, or that caused the partic ipant to discontinue the study  treatment (se e 
Section 8 .1). 
9.4.
1. Time Period and Frequency for C ollecting AE and SAE Information 
All
 AEs and SAEs will be collected from the signing of the ICF  until the follow- up visit at the time points specified 
in the SoA . 
All
 SAEs will be recorded and reported to the DCC  within 24 hours, as indicated in Appendix  4. 
The met
hod of recording, evaluating, and assessing causality of AE s and SAE s and the procedures for 
completing and transmitting SAE reports are provided in Appendix 4. 
9.4.
2. Follow -up of an AE and /or SAE 
After the initial AE/SAE report, the Investigator is required to proactively follow each participant at subs equent 
visits/contacts. All SAEs and non-s erious AESIs (as defined in Section 9.4.3), will be followed until resolution, 
until stabilizat ion, until the event is otherwise explained, or until the participant is lost to follow-u p (as defined in 
Section 8 .3). Further information on follow-u p procedures is given in Appendix 4 . 
9.4.
3. Adverse Events of Special Interest  
Som
e AEs, regardless of their severity or outcome, will be expedited due to the relevance for subject safety or 
study treatment  safety profile. These events should be reported to the DCC  within 24 hours, as indicated in 
Appendix  4. The AESIs for a lvelestat (MPH966) are:  
•Liv
er function abnormalities  defined as:
a)Any occurrence of (i) ALT or AST elevations >5  × ULN or (ii) ALT or AST >3  × ULN and total bilirubin
>2 × ULN or INR >1.5 or the appearance of worsening fatigue, nausea, vomiting, RUQ
pain/tenderness, fever, rash, or eosinophilia.
b)Any
 occurrence of <5 × ULN or ALT or AST <3  × ULN and total bilirubin <2  × ULN where the tests
have been repeated  within 48 to 72 hours and the elevation confirmed on at least 2 separate
occasions.
For participant safety and to ensure that the hepatotoxic potential of the study treatment  to be determined, a 
standardized procedure for identification, monitoring, and evaluation of liver events must be followed as 
outlined i n Section 9.3.3 a nd Section 8 .1.  
 Protocol Version 1.4  
 
 Page 31 of 59 • ECG/ Card iac Events  
 
If a study subject experiences any of the following cardiovascular events, the event should be reported 
immediately as an AESI and the study treatment  discontinued:  
 
a) Absolute QTcF >500 ms or >60 ms increase from baseline.  
 
b) Any clinically significant cardi ac abnormality  on ECG . 
 
• Infection 
 
Any new infection that requires the use of systemic antimicrobial treatment (antibiotics, anti -viral, anti -
fungal , or anti -mycobacterial) should be investigated with clinically relevant diagnostic tests.    
 
Acute exacerbations of COPD are considered AESI.  
 
• Neutropenia  
 
a) Absolute neutrophil count less than or equal to 1.0 ×  109/L on 2 consecutive repeat tests  within 48 to 
72 hours .  
 
9.4.4.  Regulatory Reporting Requirements for SAE  
 
• Prompt notification by the Investigator  to the DCC of an SAE is essential so that legal obligations and 
ethical responsibilities towards the safety of participant s and the safety of a study treatment under clinical 
investigation are met.  
 
• The DCC, the NCATS Medical Monitor,  as well as Mereo  have  a legal responsibility to notify both the 
local regulatory authority and other regulatory agencies  about the safety of a study treatment under 
clinical investigation.   
• Investigator safety reports must be prepared for suspected unexpected serious adverse reactions  
(SUSARs) according to local regulatory requirements and will be  forwarded to Investigator s as necessary.  
 
• An Investigator  who receives an Investigator  safety report describing an  SAE or other specific safety 
information ( e.g. summary or listing of SAE s) will file it along with the Investigator’s Brochure and will 
notify the IRB/IEC, if appropriate according to local requirements . 
 9.4.5.  Pregnancy 
 
• Details of all pregnancies in female participant s and female partners of male participant s will be collected 
after the start of study treatment and until 5 half -lives (4 days)  after the last dose.  
 • If a pregnancy is reported,  the Investigator  should inform  the DCC  within 24 hours of learning of the 
pregnancy and should follow the procedures outlined in Appendix 5. 
 • Abnormal pregnancy outcomes ( e.g. spontaneous abortion, fetal death, stillbirth, congenital anomalies, 
ectopic pregnancy) are considered SAEs.  
 
P rotocol Version 1.4 
P age 32 of 59 Partner Pregnancies  
P
regnancy outcomes must be collected for the female partners of the subjects who took study treatment in this 
study. Pregnancy itself is not regarded as an AE unless there is suspicion that the study treatment  may have 
interfered with the effectiveness of a contraceptive medication. If a pregnancy is reported for a subject’s partner, 
study treatment  will be immediately discontinued. The outcome of all pregnancies (spontaneous miscarriage, 
elective termination, normal birth , or congenital abnormality) must be followed and documented. A f ollow- up 
report should be sent with any new information regarding the pregnancy and the outcome of the birth.  
9.
5. Treatment of Overdose  
For
 this study, any dose of a lvelestat (MPH966) greater than 120 mg  bid within a 24 -hour time period will be 
considered an overdose.  
The
re is no specific treatment for an overdose. Any t reatment should be supportive as indicated by the subject's 
condition.  
I
n the event of an overdose, the Investigator /treating physician should:  
1.Contact the DCC and study PI  immediately .
2.Closely monitor the participant  for AE/SAE and laboratory abnormalities until alve lestat  (MPH966)  can
no l
onger be detected systemically (at least  3 days ).
3.Obtain a plasma sample for PK analysis within 3 days from the date of the last dose of study treatment if
requested by the DCC and/or study PI  (determined on a case- by-case basis) .
4.Document the quantity of the excess dose as well as the duration of the overdosing in the CRF.
D
ecisions regarding dose interruptions or modifications will be made by the Investigator  in consultation with  the 
Study PI  as necessary based on the clinical evaluation of the participant . 
9.
6. Pharmacokinetics  
S
parse PK sampling will be performed before  and after study treatment  dosing as detailed in the SoA  and MOP . 
•B
lood samples of approximately 3 mL will be collected for measurement of blood concentrations of
alvelestat (MPH966)  as specified in the SoA. Instructions for the collection and handling of biological
samples will be provided by the DCC. The actual date and time (24 -hour clock time) of each sample will
be r
ecorded.
9.7. P harmacodynamics  
Pharmacocodynamic markers form the primary, and some secondary and exploratory efficacy endpoints in 
this study  and are covered in Sec tion 9.2.1. 
 Protocol Version 1.4  
 
 Page 33 of 59 10. Statistical Considerations  
 
10.1.  Sample Size Determination   
 
Over the course of the study, approximately 60 participants will be randomized in a 1:1 ratio to receive one of 
the following:  120mg alvelestat ( MPH966) BID or placebo.  Randomization will be stratified by study site and by 
AAT genotype/phenotype.   
 
The study will be powered for within- individual change in plasma desmosine/isodesmosine as the primary 
endpoint at Week 12 compared to baseline.  A sample size of 30 participants in the MPH966  treatment group 
will give us >90% power to detect a 15% mean de crease of plasma DES from baseline to 12 weeks follow -up in 
patients treated with MPH966 (within subject change) using a two- sided paired t -test at α=0.05. This 15% mean 
decrease has been observed in trials of standard dose augmentation versus placebo 31.  A recent study of double 
dose versus single dose augmentation revealed a within subject decrease in plasma DES from 0.42 +/ -0.03 
ng/ml to 0.38 +/ - 0.03 ng/ml  12. We will have 80% power to detect a comparable difference in DES in those who 
have alvelestat added to augmentation.   
 
For comparing the mean change in DES between the two gr oups (placebo vs. MPH966), and assuming that 
there is no placebo effect over 12 weeks, a two- sided two sample t -test at α=0.05 with a sample size of 60 (30 
per group) reveals that we will have 82% power to detect a 15% difference in mean change in plasma D ES.  
 
Other secondary endpoints (BAL and sputum DES, other serum, sputum and BAL inflammatory markers, patient -
reported outcomes, and pulmonary function) will be examined within and between group with paired t -tests or 
mixed effect modeling as appropriate.    
 
We will also examine the association between DES at baseline and response to treatment as measured by 
change in pulmonary function (FEV1) over 12 weeks within the MPH966  treatment group. With a sample size of 
30, we will have 80% power to detect a 0.12 regression correlation coefficient of DES at baseline in predicting 
the change of FEV1 over 12 weeks when the standard deviation of DES is 0.10 and α=0.05.  
 
By including a 10% attrition rate over 12 weeks, the required sample size is inflated to 66 (33 p er group) to 
achieve the estimated powers. If we observe attrition rate less than we expected, we will have more statistical power to detect the expected differences. As one interim analysis will be conducted only for safety concerns (see 
Data Safety and M onitoring Plan), no adjustments to the Type I error is considered for estimating statistical 
powers.  
 
10.2.  Populations for Analyses 
 
For purposes of analysis, the following populations are defined:  
 
Population  Description  
Enrolled Set The Enrolled Set will include a ll participants who sign the ICF . 
Random ized Set The Random ized Set will include all subjects who signed the ICF  and were 
subsequently random ized into the study, regardless of study treatment 
administration.   
Full Analysis Set  The Full Analysis Set will serve as the primary population for the analysis of 
efficacy and will consist of all random ized subjects who took at least 1 dose 
of double- blind study treatment and have at least 1 evaluable change from 
baseline in plasma desmosine/isodesmosine levels. Subjects will be 
analyzed according to random ized treatment.  
 Protocol Version 1.4  
 
 Page 34 of 59 Population  Description  
Per-Protocol Set  The Per -Protocol Set includes all participants from the Full Analysis Set who 
have been treated according to the protocol and fulfil the following criteria:  
1. All inclusion/exclusion criteria satisfied  
2. Absence of relevant protocol violations with respect to factors l ikely 
to affect the efficacy of treatment where the nature of protocol 
violation will be defined before breaking the blind  
3. Adequate study medication compliance,  which will be determined 
before breaking the blind 
Subjects will be analy sed according to random ized treatment.  
Safety  Set All random ized participants who take at least 1 dose of study treatment. 
Participants will be analy sed according to random ized treatment.  
PK Set  The PK Set will include all participants in the Safety Set who have at least 1 
evaluable serum concentration.  
 
10.3.  Statistical Analyses  
 
The statistical analysis will be performed using SAS® version 9. 4 or higher. The main population for efficacy 
analysis will be the Full Analysis Set ; supportive analyses will also be performed using the Per -Protocol Set .  
 
Continuous data will be presented using descriptive summaries (e.g., mean, standard deviation, minimum, 
maximum, median, lower quartile,  and upper quartile) . Categorical variables will be presented by the number of 
observations and relative (%) frequency.   
Unless otherwise stated, baseline value for any variable will be the last value ta ken prior to the first dose of study 
medication.  
 
Unless otherwise stated, all statistical tests will be 2 -sided and conducted at the 5% level. All presented 
confidence intervals will be 2 -sided 95% confidence intervals . 
 
The Statistical Analysis Plan ( SAP)  will be developed and final ized before database lock and will describe the 
selection of participants to be included in the analyses and procedures for accounting for missing, unused, and 
spurious data. Below is a summary of planned statistical analyses of the primary and secondary endpoints.  
 
10.3.1.  Efficacy Analyses  
 
Endpoint  Statistical Analysis Methods  
Primary  Within individual % change from baseline in plasma desmosine/isodesmosine levels at 12 
weeks will be calculated. An analysis of covariance (ANCOVA) model with baseline plasma 
desmosine/isodesmosine levels as a covariate and treatment and sputum strata as factors 
will be used to generate least squared means and least squared mean differences between 
treatment groups.   
Secondary  The biomarker  correlation analysis will be done using stepwise approach:  
The parameters in BAL, sputum , and blood during treatment will be compared to the baseline 
values for active and placebo patients separately to evaluate natural variability of the 
markers.  
 
The time- matched biomarker values will be compared between placebo and active groups 
to assess the differences outside natural variability and time to significant change for the 
responsive biomarkers.  
 
 Protocol Version 1.4  
 
 Page 35 of 59 Endpoint  Statistical Analysis Methods  
Multiple models , including non -parametric models , will be considered within this frame 
incorporating different covariates and data transformations. PD parameters such as area 
under the effect -time curve will also be considered.  
 
Principal component multifactorial analysis and/or c luster analysis may be e mployed to 
simplify the comparison  and to explore the treatment effect . Decisions will be made on review 
of data and prior to database lock.  
 
Correlation of select biomarkers shown to be responsive to treatment with time -matched 
drug concentrations and PK parameters , if available , may be used to evaluate exposure-
response r elationship .   
Exploratory  Observed values and change from baseline in FEV 1, FVC, FEV 1/FVC ( total and percent 
predicted) and maximal mid- expiratory flow will be presented by treatment group and study 
visit. Change from baseline at W eek 12 will be analy sed using an ANCOVA model . 
 
Observed values and change from baseline for the total and  component scores of the 
SGRQ -C will be presented by treatment group and study visit. Change from baseline in total 
score at Week 12 will be analy sed using an ANCOVA model.  
 Correlation of select biomarkers shown to be responsive to treatment with time -matched 
drug concentrations and PK parameters , if available,  will be used to evalu ate exposure -
response relationship.  
 
 
 
10.3.2.  Safety Analyses  
 All safety analyses will be performed on the Safety Set .  
 
Endpoint  Statistical Analysis Methods  
Primary  AEs will be coded using the Medical  Dictionary for Regulatory Activities (MedDRA). 
Summaries will be by system organ class and preferred term. Treatment -emergent AEs 
are defined as any AE occurring or worsening on or after the first dose of study medication. 
If a participant experiences the same preferred term multiple times , the event will be 
counted only once overall and by the greatest severity.  
 
The frequency and incidence of treatment -emergent AEs will be presented by system 
organ class and preferred term for each treatment group (number  and percentage of 
participants experiencing at least 1 AE per preferred term as well as the number of 
observed events per preferred term). Separate tables will be presented by severity and by relationship. All AEs will be presented in full in a comprehens ive listing including participant 
number, treatment regimen, severity, seriousness, action taken, outcome, relationship to 
treatment, onset/stop , and duration. Details of SAEs and AEs leading to withdrawal will be 
listed separately.  
 
Adverse Events of Special Interest  
AESIs,  including liver function abnormalities , ECG/cardiac  events , infections , and 
neutropenia , will be tabulated and summar ized by treatment group and overall .  
Secondary  Vital Signs  
 Protocol Version 1.4  
 
 Page 36 of 59 Endpoint  Statistical Analysis Methods  
Vital signs will be summar ized as observed values and change from baseline by treatment 
group and overall.  
 
Physical Examination  
Physical examination results will be listed by subject ID and body system.  
 ECG  
ECG parameters will be summar ized as observed values and change from baseline by 
treatment group and study visit.  
 
Abnormal findings (“n ormal” , “abnormal, not clinically significant” , and “ abnormal, clinically 
significant”) will be summar ized by the number and percentage within each category , and 
change from baseline will be summar ized by shift tables.  
 
Clinical Laboratory  
Laboratory parameters will be summar ized as observed values and change from baseline 
by treatment group and study visit.  
 
Values outside the normal range will be summar ized by the number and percentage within 
each category, and  change from baseline will be summar ized by shift tables.  
 
Safety and  PK Relationships  
The safety correlation analysis with drug concentration may be done for the safety 
parameters shown to be sensitive to alvelestat exposure. The comparison of exposure will 
be done between groups with non -clinically significant changes and clinically significant 
changes in safety parameters using graphic and statistical methods where data allow.  
 
Exploratory  The details w ill be described in the SAP finalized before  database lock . 
  
10.3.3.  Other Analyses  
 PK, PD, and b iomarker exploratory analyses will be described in the SAP finalized before  database lock.  
 10.3.4.  Interim Analyses   
 
No interim analysis for efficacy is planned for this study .  An interim safety analysis will be conducted when 30 
subjects have completed the study.  
 Protocol Version 1.4  
 
 Page 37 of 59 11. References  
 
1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of 
chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347 -
65. 
2. Centers for Disease C, Prevention. Chronic obstructive pulmonary disease among adults --United 
States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:938 -43. 
3. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive 
pulmonary disease: a clinical practice guideline update from the American College of Physicians, American 
College of Chest Physicians, American Thoracic Society, and European Respirator y Society. Ann Intern Med 
2011;155:179 -91. 
4. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and 
Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol 
2017;53:128 -49. 
5. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269- 80. 
6. Wells JM, O'Reilly PJ, Szul T, et al. An aberrant leukotriene A4 hydrolase- proline- glycine -proline 
pathway in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 
2014;190:51 -61. 
7. Stoller JK, Aboussouan LS. Alpha1- antitrypsin deficiency. Lancet 2005;365:2225- 36. 
8. Stoller JK, Aboussouan LS. A review of alpha1- antitrypsin deficiency. Am J Respir Crit Care Med 
2012;185:246 -59. 
9. Greul ich T. Alpha- 1-Antitrypsin Deficiency: Disease Management and Learning from Studies. COPD 
2017;14:S8- S11. 
10. Silverman EK, Sandhaus RA. Clinical practice. Alpha1- antitrypsin deficiency. N Engl J Med 
2009;360:2749 -57. 
11. Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in 
severe alpha1 antitrypsin deficiency (RAPID): a randomised, double- blind, placebo- controlled trial. Lancet 
2015;386:360 -8. 
12. Campos MA, Geraghty P, Holt G, et al. The Biological Effects of  Double- Dose Alpha- 1 Antitrypsin 
Augmentation Therapy. A Pilot Clinical Trial. Am J Respir Crit Care Med 2019;200:318 -26. 
13. Cosio MG, Bazzan E, Rigobello C, et al. Alpha- 1 Antitrypsin Deficiency: Beyond the 
Protease/Antiprotease Paradigm. Ann Am Thorac S oc 2016;13 Suppl 4:S305- 10. 
14. Ferrarotti I, Corsico AG, Stolk J, et al. Advances in Identifying Urine/Serum Biomarkers in Alpha- 1 
Antitrypsin Deficiency for More Personalized Future Treatment Strategies. COPD 2017;14:56- 65. 
15. Greene CM, Marciniak SJ, Teckman J, et al. alpha1- Antitrypsin deficiency. Nat Rev Dis Primers 
2016;2:16051.  
16. Duvoix A, Roussel BD, Lomas DA. Molecular pathogenesis of alpha- 1-antitrypsin deficiency. Rev Mal 
Respir 2014;31:992- 1002.  
17. Chamba A, Afford SC, Stockley RA, Burnett D . Extracellular proteolysis of fibronectin by neutrophils: 
characterization and the effects of recombinant cytokines. Am J Respir Cell Mol Biol 1991;4:330- 7. 
18. Wells JM, Gaggar A, Blalock JE. MMP generated matrikines. Matrix Biol 2015;44- 46:122- 9. 
19. Russell DW, Wells JM, Blalock JE. Disease phenotyping in chronic obstructive pulmonary disease: the 
neutrophilic endotype. Curr Opin Pulm Med 2016;22:91 -9. 
 Protocol Version 1.4  
 
 Page 38 of 59 20. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: curr ent 
status and future directions. Eur Respir J 2008;32:1146- 57. 
21. Pelham F, Wewers M, Crystal R, Buist AS, Janoff A. Urinary excretion of desmosine (elastin cross -
links) in subjects with PiZZ alpha- 1-antitrypsin deficiency, a phenotype associated with hereditary 
predisposition to pulmonary emphysema. Am Rev Respir Dis 1985;132:821- 3. 
22. Turino GM, Lin YY, He J, Cantor JO, Ma S. Elastin degradation: an effective biomarker in COPD. 
COPD 2012;9:435- 8. 
23. Ma S, Turino GM, Lin YY. Quantitat ion of desmosine and isodesmosine in urine, plasma, and sputum 
by LC -MS/MS as biomarkers for elastin degradation. J Chromatogr B Analyt Technol Biomed Life Sci 
2011;879:1893 -8. 
24. Deslee G, Woods JC, Moore CM, et al. Elastin expression in very severe human COPD. Eur Respir J 
2009;34:324 -31. 
25. Ma S, Lin YY, Turino GM. Measurements of desmosine and isodesmosine by mass spectrometry in 
COPD. Chest 2007;131:1363- 71. 
26. Stolk J, Veldhuisen B, Annovazzi L, et al. Short -term variability of biomarkers of protei nase activity in 
patients with emphysema associated with type Z alpha- 1-antitrypsin deficiency. Respir Res 2005;6:47.  
27. Bihlet AR, Karsdal MA, Sand JM, et al. Biomarkers of extracellular matrix turnover are associated with 
emphysema and eosinophilic -bronchitis in COPD. Respir Res 2017;18:22.  
28. He J, Turino GM, Lin YY. Characterization of peptide fragments from lung elastin degradation in chronic 
obstructive pulmonary disease. Exp Lung Res 2010;36:548 -57. 
29. Senior RM, Griffin GL, Mecham RP, Wrenn DS, P rasad KU, Urry DW. Val -Gly-Val-Ala-Pro-Gly, a 
repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J Cell Biol 1984;99:870 -4. 
30. Stolz D, Leeming DJ, Kristensen JH, et al. Systemic Biomarkers of Collagen and Elastin Turnover Are 
Associated With Clinically Relevant Outcomes in COPD. Chest 2017;151:47- 59. 
31. Ma S, Lin YY, He J, Rouhani FN, Brantly M, Turino GM. Alpha- 1 antitrypsin augmentation therapy and 
biomarkers of elastin degradation. COPD 2013;10:473- 81. 
32. Stevens T, Ekholm K,  Granse M, et al. AZD9668: pharmacological characterization of a novel oral 
inhibitor of neutrophil elastase. J Pharmacol Exp Ther 2011;339:313 -20. 
33. Vogelmeier C, Aquino TO, O'Brien CD, Perrett J, Gunawardena KA. A randomised, placebo- controlled, 
dose- finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive 
pulmonary disease treated with tiotropium. COPD 2012;9:111- 20. 
34. Kuna P, Jenkins M, O'Brien CD, Fahy WA. AZD9668, a neutrophil elastase inhibitor, plus ongoing 
budesonide/formoterol in patients with COPD. Respir Med 2012;106:531 -9. 
35. Elborn JS, Perrett J, Forsman- Semb K, Marks -Konczalik J, Gunawardena K, Entwistle N. Efficacy, 
safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J  2012;40:969- 76. 
36. Gunawardena KA, Gullstrand H, Perrett J. Pharmacokinetics and safety of AZD9668, an oral neutrophil 
elastase inhibitor, in healthy volunteers and patients with COPD. Int J Clin Pharmacol Ther 2013;51:288- 304. 
37. Stockley R, De Soyza A , Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor 
(AZD9668) in patients with bronchiectasis. Respir Med 2013;107:524- 33. 
38. Nordenmark LH, Taylor R, Jorup C. Feasibility of Computed Tomography in a Multicenter COPD Trial: 
A Study o f the Effect of AZD9668 on Structural Airway Changes. Adv Ther 2015;32:548 -66. 
39. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic 
obstructive pulmonary disease pharmacotherapy: making progress towards personalis ed management. Lancet 
2015;385:1789 -98. 
 Protocol Version 1.4  
 
 Page 39 of 59 40. Ma S, Lin YY, Cantor JO, et al. The Effect of Alpha- 1 Proteinase Inhibitor on Biomarkers of Elastin 
Degradation in Alpha- 1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. Chronic 
Obstr Pu lm Dis 2016;4:34- 44. 
41. Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and management of patients with 
alpha1- antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol 2012;10:575- 80. 
42. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict 
significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317- 25. 
43. Meguro M, Barley EA, Spencer S, Jones PW. Development and Validation of an Improved, COPD -
Specific Version of the St. George Respiratory Questionnaire. Chest 2007;132:456 -63. 
44. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of 
the COPD Assessment Test. Eur Respir J 2009;34:648- 54. 
45. Comstock GW, Tockman MS, Helsing KJ, Hennesy KM. Standardized respiratory questionnaires: 
comparison of the old with the new. Am Rev Respir Dis 1979;119:45- 53. 
46. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the 
UCSD Shortness of Breath Questionnai re. University of California, San Diego. Chest 1998;113:619- 24. 
47. Damilakis J, Adams JE, Guglielmi G, Link TM. Radiation exposure in X -ray-based imaging techniques 
used in osteoporosis. Eur Radiol 2010;20:2707- 14. 
 
 Protocol Version 1.4  
 
 Page 40 of 59 12. Appendices  
 Protocol Version 1.4  
 
 Page 41 of 59 Appendix  1:  Abbreviations, Trademarks & Glossary 
Abbreviation  Description  
AAT Alpha- 1antitrypsin 
AATD Alpha- 1 antitrypsin deficiency  
Aα-Val360  Fragment from neutrophil elastase cleavage of elastin at Aα- Val360 site  
AcPGP  Acetylated Proline -Glycine -Proline  
AE Adverse event  
AESI  Adverse event of special interest  
ALT Alanine aminotransferase 
ANCOVA Analysis of covariance  
AST Aspartate aminotransferase 
AUC Area under the curve  
BAL Bronchoalveolar lavage  
bid Twice (2 times) a day  
C1M  MMP -derived collagen type I breakdown fragment  
C6M  MMP -derived collagen type VI breakdown fragment  
CAT COPD assessment test  
Cat g  Cathepsin G  
CF Cystic fibrosis  
CFR United States Code of Federal Regulations  
CMP  Complete metabolic profile  
CMV  Cytomegalovirus  
CONSORT  Consolidated Standards of Reporting Trials  
COPD Chronic obstructive pulmonary disease  
CRF Case report form  
CRO  Clinical Research Organization 
CT Computerized or computed tomography  
 Protocol Version 1.4  
 
 Page 42 of 59 CYP2C9  Cytochrome P450 2C9  
DCC  Data Coordinating Center  
DES Desmosine 
dL Decilitre  
DSMB Data Safety Monitoring Board  
EBV Epstein- Barr virus  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EL-CG Elastin degradation mediated by Cathepsin G  
EL-NE Elastin degradation mediated by NE  
EL-P3 Elastin like polypeptide 3  
EOT End of treatment  
EP-3 Elastin peptide 3  
FEV1  Forced expiratory volume in 1 second  
FEV1/FVC  Forced expiratory volume in 1 second divided by the forced vital capacity  
FVC Forced vital capacity  
FIB-4 Fibrosis -4 
FU Follow -up 
FVC Forced vital capacity  
g Gram  
GCP  Good Clinical Practice  
h Hour  
hCG  Human chorionic gonadotropin  
HIV Human immunodeficiency virus  
hsCRP  High-sensitivity C -reactive protein 
HRT Hormone replacement therapy  
 Protocol Version 1.4  
 
 Page 43 of 59 HSV Herpes simplex virus  
Hy’s Law  a rule of thumb that a patient is at high risk of a fatal drug- induced liver injury (DILI) 
if given a medication that causes hepatocellular injury (not cholestatic injury) with 
jaundice  
IC50  the concentration of an inhibitor where the response (or binding) is reduced by half  
ICF Informed consent form  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IL-1β Interleukin 1 beta  
IL-6 interleukin- 6 
IL-8 interleukin- 8 
IND Investigational new drug  
INR International normalized ratio  
IRB Institutional Review Board 
IWRS  Interactive web response system  
Ki Inhibitory constant  
kPa kiloPascal, a unit of force  
LSM  Liver stiffness measurement  
LTB4  Leukotriene b4  
MedDRA Medical Dictionary for Regulatory Activities  
mGy  milliGray, a unit of radiation 
mg/dL  Milligrams per decilitre  
mIU Milli International Units  
MMP  Matrix metalloproteinase 
MMRC  Modified medical research council  
MOP  Methods of procedures  
MPO  Myeloperoxidase  
 Protocol Version 1.4  
 
 Page 44 of 59 MS Millisecond  
mSV milliSever  
NCATS  National Center for Advancing Translational Science 
NCT National Clinical Trial  
NE Neutrophil elastase  
NIH National Institutes of Health 
NOAEL  No observed adverse effect level  
NSAID  Non-steroidal anti -inflammatory drug  
Pa Pascal  
PD Pharmacodynamics  
PI Principal investigator  
Pi*ZZ  Alpha- 1 ZZ genotype  
Pi*SZ  Alpha- 1 SZ genotype  
Pi*Null, Null  Alpha- 1 Null genotype  
PGP P-glycoprotein  
PK Pharmacokinetics  
PR time from the onset of the P wave to the start of the QRS complex on ECG  
PR3 Proteinase 3  
PROs  Patient reported outcomes  
PRO -C6 Released C -terminal pro -peptide of type VI collagen 
QRS  Represents ventricular depolarization on ECG  
QT The duration of ventricular depolarization and repolarization on ECG  
QTc Corrected QT interval  
QTcF  QTc by Fridericia’s correction method  
QTcV  QTc by Van de Water’s correction formula 
RANTES  Regulated on activation, normal T cell expressed and secreted  
 Protocol Version 1.4  
 
 Page 45 of 59 RBC  Red blood cell 
SAE Serious adverse event  
SAP Statistical Analysis Plan  
SAS Statistical analysis software  
SGRQ -C St. George’s Respiratory Questionnaire compact version 
SoA Schedule of Activities  
SOB  Shortness of breath  
SOP Standard operating procedure  
SOBQ  Shortness of breath questionnaire  
Sp02 Pulse oximetry  
SUSAR  Suspected Unexpected Serious Adverse Reaction 
TB Total bilirubin 
ug Microgram  
ULN Upper limit of normal  
uM Micromolar  
UPs Unanticipated problems  
VZV Varicella zoster virus  
WBC White blood cell  
Wk. Week  
  
P rotocol Version 1.4 
P age 46 of 59 Appendix  2:  Clinical Laboratory Tests 
•The t
ests detailed in the table below will be performed by the local laborator ies.
•Protocol-s pecific requirements for inclusion or exclus ion of participants are detailed in Section 6.1 or  
Section 6.2, respectively.
•A
dditional tests may be performed at any time during the study as determined necessary by the
Investigator  or required by local regulations.
P
rotocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Platelet Count  
RBC Count  
Hemoglobin 
Hematocrit  MCV  
MCH 
%Reticulocytes  WBC count with 
differential (% and absolute counts):  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  Prothrombin Time (PT)  
Partial prothromboplastin time (PTT)  
International normalized ratio 
(INR)  
Clinical 
Chemistry1 Blood urea 
nitrogen  Potassium  AST/Serum 
glutamic -
oxaloacetic transaminase 
(SGOT)  Total and direct bilirubin  
Creatinine and 
estimated glomerular filtration rate 
clearance  Sodium  ALT/Serum 
glutamic -pyruvic 
transaminase (SGPT)  Total protein  
Alkaline 
phosphatase  Calcium  
Other 
Screening 
Tests  •Urine pregnancy test during the study (as needed for women of childbearing potential)
•Serum human chorionic gonadotropin pregnancy test (as needed for women of
childbearing potential) 
•Alpha- 1 antitrypsin blood protein levels
•Serology (HIV antibody, hepatitis B surface antigen and hepatitis B antibody, and hepatitis
C virus antibody)
•All study -required laboratory assessments will be performed at the local laboratory, with
the exceptions of the samples (blood, sputum, BAL) that will be sent to a central laboratory
for curation and analysis.
•The results of each test must be entered into the CRF as guided by the CRF Completion
Guidelines.
1 Details of liver chemistry stopping criteria and required ac tions and follow-u p asses sments after liver 
stopping or monitoring event are given in Section 8.1. All events of ALT ≥3 × ULN and bilirubin ≥2 × ULN 
(>35% direct bilirubin) or ALT ≥3 × ULN and INR >1.5, if INR is measured, which may indicate severe liver 
injury (poss ible Hy’s Law), must be reported as an SAE. 2 Local urine testing will be standard. 
I
nvestigators must document their review of each laboratory safety report.  
 Protocol Version 1.4  
 
 Page 47 of 59 Appendix 3:  Study Governance Considerations 
Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
o Consensus ethical principles derived from international guidelines including the Declaration of Helsinki 
and Council for International Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines . 
o Applicable International C onference on Harmoni zation ( ICH) Good Clinical Practice  (GCP) Guidelines . 
o Applicable laws and regulations  under the IND . 
 
• The protocol, protocol amendments, ICF , Investigator ’s Brochure , and other relevant documents ( e.g., 
advertisements) must be submitted to an IRB  by the Investigator  and revi ewed and approved by the IRB  & 
Competent Authority/Regulatory Authority  before the study is initiated.   
 • Any amendment s to the protocol will require IRB approval before implementation of changes made to the 
study design, except for changes necessary to eliminate an immediate hazard to study participant s.  
 • The Investigator  will be responsible for  the following : 
o Providing written summaries of the status of the study to the IRB  annually or more frequently in 
accordance with the requirements, policies, and pr ocedures established by the IRB . 
o Notifying the IRB  of SAEs or other significant safety findings as required by IRB  procedures . 
o Overall conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the 
IRB, and all other applicable local regulations . 
 
Financial Disclosure  
Principal Investigators and Site Investigators  will provide the DCC  and the Sponsor  with sufficient, accurate 
financial information in accordance with local regulations to allow the Sponsor  to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory  authorities.  Investigators are 
responsible for providing information on financial interests during the course of the study and for 1 year  after 
completion of the study.  
 
Informed Consent Process  
• The Site Investigator  or his/her representative will explain the nature of the study to the participant  or 
his/her legally author ized representative and answer all questions regarding the study.  
 
• Participant s must be informed that their participation is voluntary. Participant s will be required to sign a 
statement of informed consent that meets the requirements of 21  CFR 50, local regulations, ICH 
guidelines, Health Insurance Portability and Accountability Act ( HIPAA)  requirements , where applicable, 
and the IRB or study site .  
 
• The source documentation and CRF must include a statement that written informed consent was 
obtained before the participant  was enrolled in the study and the date the written consent was obtained. 
The author ized person obtaining the informed consent must also sign the ICF.  
 
• Participant s must be re- consented to the most current version of the ICF(s)  during th eir participation in 
the study.  
 
• A copy of the ICF(s)  must be provided to the participant  or his/her legally author ized representative.  
 Protocol Version 1.4 
 
 Page 48 of 59 Data Management 
 The study will use an electronic data entry system (eDES), a w eb-based platform used for data entry, 
curation, archiving, and notification.  The eDES was developed and is managed by the DCC. 
 CRFs can be printed from the eCRF generated by and available t hrough the eDES.  The Site Investigator 
/ Site PI will be responsible for data entry into the system.  The DCC will monitor for data quality and will 
query sites as needed.   
 Oversight for the study will be done via risk-based monitoring . 
 The DCC will centrally monitor sites can provide on-site monit oring if needed for any high risk clinical site 
(e.g. those with data anomalies or a higher frequency of errors , protocol violations, or dropouts relative 
to other site).   
 If adverse events require hospitalization, study participants will be cared for by the hospital staff at the 
local sites as per local policy. The study team will monitor th e status of the patient while hospitalized, but 
will not be required to provide all aspects of care for these i ndividuals 
 
Data Protection 
 Participants will be assigned a unique identifier by the DCC. Any participant records or datasets that are 
transferred to the DCC will contain the identifier only; partic ipant names or any information that would 
make the participant identifiable will not be transferred.  
 
 The participant must be informed that his/her personal study-r elated data will be used by the DCC in 
accordance with local data protection law. The level of disclos ure must also be explained to the 
participant.  
 
 The participant must be informed that his/her medical records may be examined by Clinical Quality 
Assurance auditors or other authorized personnel appointed by t he DCC, Mereo BioPharma, by 
appropriate IRB members, and by inspectors from regulatory auth orities. 
Data Quality Assurance 
 All participant data relating to the study will be recorded on  printed or electronic CRF unless transmitted 
to the DCC or designee electronically (eg, laboratory data). Th e Investigator is responsible for verifying 
that data entries are accurate and correct by physically or ele ctronically signing the CRF.  
 
 The Investigator must maintain accurate documentation (source data) that supports the information 
entered in the CRF.  
 
 The Investigator must permit study-related monitoring, audits,  IRB review, and regulatory agency 
inspections and provide direct access to source data documents.   
 
 The Sponsor or designee is responsible for the data management  of this study, including quality checking 
of the data.  
 
 Records and documents, including signed ICF, pertaining to the  conduct of this study must be retained 
by the Investigator for 25 years after study completion unless local regulations or institutional policies 
require a longer retention period. No records may be destroyed during the retention period without the 
written approval of the NIH. No records may be transferred to a nother location or party without written 
notification to the NIH and the DCC.  
 Protocol Version 1.4 
 
 Page 49 of 59 Source Documents 
 Source documents provide evidence for the existence of the par ticipant and substantiate the integrity of 
the data collected. Source documents are filed at the Investiga tor’s site. 
 
 Data reported on the CRF or entered in the electronic CRF that  are transcribed from source documents 
must be consistent with the source documents or the discrepanci es must be explained. The Investigator 
may need to request previous medical records or transfer record s, depending on the study. Also, current 
medical records must be available. 
 
 Definition of what constitutes source data can be found in the  Study Manual and Monitoring Plan. 
 
Study and Site Closure 
The NIH, Mereo, UAB, the FDA, the IRB, or a designee may stop t he study or study site participation in the study 
for medical, safety, regulatory, administrative, or other reaso ns consistent with applicable laws, regulations, and 
GCP.  
 
 Protocol Version 1.4  
 
 Page 50 of 59 Appendix 4:  Adverse Events: Definitions and Procedures for Recording, Evaluating,  Follow -up, and 
Reporting  
AE Definition  
• An AE is any untoward medical occurrence in a clinical trial subject administered a medicinal product and 
which does not necessarily have a causal relationship with this treatment.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal 
product.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety 
assessments ( e.g., ECG , radiological scans, vital signs measurements), including those that worsen from 
baseline, considered clinically significant in the medical and scientific judgment  of the Investigator  (i.e., not 
related to progression of underlying disease) . 
• Exacerbation of a chronic or intermittent pre -existing  condition including either an increase in frequency 
and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even though it may have been 
present before the start of the study.  
• Signs, symptoms, or the cl inical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication . Overdose per se will not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self -harming intent.  Such overdoses should be reported regardless 
of sequelae.  
• “Lack of efficacy ” or “failure of expected pharmacological action”  per se will not be reported as an AE /SAE.  
Such instances will be captured in the efficacy assessments.  However, the signs, symptoms, and/or clinical 
sequelae resulting from lack of efficacy  will be reported as AE /SAE if they fulfil the definition of an AE /SAE.   
 
Events NOT  Meeting the AE D efinition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the Investigator  to be more severe than expected 
for the participant ’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe than expected for the participant ’s condition.  
• Medical or surgical procedure ( e.g., endoscopy, appendectomy): the conditi on that leads to the procedure 
is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission 
to a hospital).  
• Anticipated day -to-day fluctuations of pre-existing  disease(s) or condition(s) present or detect ed at the start 
of the study that do not worsen.  
 
Unanticipated Problem  (UP) Definition  
• In general, an AE observed during the conduct of a study should be considered an Unanticipated Problem 
(UP) involving risk to human subjects, and reported to the IRB, only if it were unexpected, serious, and 
would have implications for the conduct of the study (e.g., requiring a significant, and usually safety -related, 
change in the protocol such as revising inc lusion/exclusion criteria or including a new monitoring 
requirement, informed consent, or investigator’s brochure).   
• An individual AE occurrence ordinarily does not meet these criteria because, as an isolated event, its 
implications for the study cannot be understood.   
 Protocol Version 1.4  
 
 Page 51 of 59 • AEs listed in the Investigator’s Brochure (IB) are not by definition UPs because they have been previously 
observed with a drug, and would not be considered unexpected and thus would not be unanticipated 
problems.  
• Possible exceptions would include situations in which the specificity or severity of the event is not consistent 
with the description in the investigator’s brochure, or it can be determined that the observed rate of 
occurrence for a serious, expected AE in the clinical trial represents a clinically important increase in the 
expected rate of occurrence  
 
Events Meeting  UP Definition  
• A single occurrence of a serious, unexpected event that is uncommon and strongly associated with drug 
exposure (such as angioe dema, agranulocytosis, hepatic injury, or Stevens -Johnson syndrome).  
• A single occurrence, or more often a small number of occurrences, of a serious, unexpected event that is not commonly associated with drug exposure, but uncommon in the study population (e.g., tendon rupture, 
progressive multifocal leukoencephalopathy).  
• Multiple occurrences of an AE that, based on an aggregate analysis, is determined to be an unanticipated 
problem. There should be a determination that the series of AEs represents a signal that the AEs were not just isolated occurrences and involve risk to human subjects (e.g., a comparison of rates across treatment 
groups reveals higher rate in the drug treatment arm versus a control).  
• 
An AE that is described or addressed in the investig ator’s brochure, protocol, or informed consent 
documents, but occurs at a specificity or severity that is inconsistent with prior observations. For example, 
if transaminase elevation is listed in the investigator’s brochure and hepatic necrosis is observed in study 
subjects, hepatic necrosis would be considered an unanticipated problem involving risk to human subjects.  
• A serious AE that is described or addressed in the investigator’s brochure, protocol, or informed consent documents, but for which the rate of occurrence in the study represents a clinically significant increase in 
the expected rate of occurrence (ordinarily, reporting would only be triggered if there were a credible 
baseline rate for comparison).  
• Any other AE or safety finding (e.g., based on animal or epidemiologic data) that would cause the sponsor 
to modify the investigator’s brochure, study protocol, or informed consent documents, or would prompt 
other action by the IRB to ensure the protection of human subjects.  
 
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met ( e.g., 
hospitali zation for signs/symptoms of the disease under study, death due to progression of disease).  
 
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  or; 
b. Is life -threatening  or; 
The term “life-threatening”  in the definition of “serious ” refers to an event in which the participant  was at risk of 
death at the time of the event.  It does not refer to an event, which hypothetically might have caused death, if it 
were more severe.  
c. Requires  inpatient  hospitali zation or prolongation of existing hospitali zation  or; 
In general, hospital ization signifies that the participant  has been detained (usually involving at least an overnight 
stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate 
in the physician’s office or out patient setting.  Complications that occur during hospitali zation are AE s. If a 
complication prolongs hospitali zation or fulfils any other serious criteria, the event is serious.  When in doubt as 
to whether “hospitali zation” occurred or was necessary, the A E should  be considered serious.  
 Protocol Version 1.4  
 
 Page 52 of 59 Hospitali zation for elective treatment of a pre -existing condition that did not worsen from baseline is not 
considered an AE.  
d. Results in persistent disability/incapacity  or; 
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrho ea, influenza, and accidental trauma (eg, sprained 
ankle) that may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption . 
e. Is a congenital anomaly/birth defect  or; 
f. Other situations:  
• Medical or scientific judgment should be exercised in deciding whe ther SAE reporting is appropriate in 
other situations such as important medical events that may not be immediately life- threatening or result in 
death or hospitali zation but may jeopardi ze the participant  or may require medical or surgical intervention 
to prevent one of the other outcomes listed in the above definition.  These events should usually  be 
considered serious . 
Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room 
or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitali zation, 
or development of drug dependency or drug abuse . 
 
 
 
Recording AE s and SAE s 
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all documentation ( e.g., 
hospital progress notes, laboratory, and diagnostics reports) related to the event.  
• The Investigator  will then record all relevant AE/SAE information in the CRF.  
• It is not  acceptable for the Investigator  to send photocopies of the participant ’s medical records to the DCC  
in lieu of completion of the AESI /AE/SAE CRF page.  
• There may be instances when copies of medical records for certain cases are requested by the DCC . In 
this case , all participant  identifiers, with the exception of the participant  number, will be blinded on the 
copies of the medical records before  submission to the DCC.  
• The Investigator  will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other 
clinical information.  In such cases, the diagnosis (not the individual signs/symptoms) will be documented 
as the AE/SAE.  
Assessment of Intensity  
The Investigator  will make an assessment of intensity for each AE and SAE reported during the study and 
assign it to one of the following categories:   
• Mild:  An event that is easily tolerated by the participant , causing minimal discomfort and not interfering with 
everyday activities.  
• Moderate:  An event that causes  sufficiently discomfort and interfere s with normal everyday activities . 
• Severe:  An event that prevents normal everyday activities. A n AE that is assessed as severe shou ld not 
be confused with an SAE. Severe is a category util ized for rating the int ensity of an event; and both AE s 
and SAE s can be assessed as severe.  
An event is defined as “serious ” when it meets at least one  of the predefined outcomes as described in the 
definition of an SAE , NOT when it is rated as severe.  
 Protocol Version 1.4  
 
 Page 53 of 59 Assessment of Causality  
• The Investigator  is obligated to assess the relationship between study treatment and each occurrence of 
each AE/SAE.  
• A “reasonable possibility ” of a relationship convey s that there are facts , evidence,  and/or arguments to 
suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The Investigator  will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease( s), concomitant therapy, and other risk factors, as well as 
the temporal relationship of the event to study treatment administration will be considered and investigated.  
• The Investigator  will also consult the Investigator ’s Brochure and/or Product Information, for marketed 
products, in his/her assessment.  
• For each AE/SAE,  the Investigator  must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator  has minimal information to 
include in the initial report to.  However, it is very important that the Investigator  always make an 
assessment of causality for every event before the initial transmission of the SAE data to the DCC.  
• The Investigator  may change his/her opinion of causality in light of follow -up information and send an SAE 
follow- up report with the updated causality assessment . 
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
Follow -up of AE and SAE  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental measurements and/or 
evaluations as medically indicated or as requested by the DCC to elucidate the nature and/or causality of 
the AE or SAE as fully as possible.  This may include additiona l laboratory tests or investigations, 
histopathological examinations , or consultation with other health care professionals.  
• If a participant  dies during participation in the study or during a recognized  follow- up period, the Investigator  
will provide the DCC with a copy of any postmortem findings including histopathology.  
• New or updated information will be recorded in the originally completed CRF.  
• The Investigator  will submit any updated SAE data to the DCC within 24 hours of receipt of  the information.  
SAE Reporting to DCC  via eCRF 
• SAEs will be reported to the DCC via the eCRF.  
• Initial reporting can be updated when additional information is obtained but this should not delay 
submission.  
 
Suspected Unexpected Serious Adverse Reaction (SUSAR)  
• An adverse reaction (AR) is any untoward or unfavorable medical occurrence in a clinical research study 
participant, including any abnormal sign (e.g. abnormal physical exam or laboratory finding), symptom, or 
disease, temporally associat ed with the participants’ involvement in the research, whether or not considered 
related to participation in the research.  
• An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed . 
• SUSAR events are AR events that fulfil criteria for seriousness (outlined in SAE above).  SUSARs should 
be reported to the DCC, NIH/NCATS, Mereo, and the FDA using the instructions listed fo r SAE reporting.  
 
 
 Protocol Version 1.4  
 
 Page 54 of 59 Appendix  5:  Contraceptive Guidance and Collection of Pregnancy Information  
 
Alvelestat (MPH966) has a low genotoxic potential and reproductive toxicology studies have not demonstrated 
any effects in either the reproductive function or in embryo- fetal development. Therefore, the following 
precautions are required to protect women of childbearing potential and female partners of males in the study.  
 
Definitions  
Woman of Childb earing Potential  
 
A woman is considered fertile following menarche and until becoming postmenopausal unless permanently 
sterile. Permanent sterili zation methods include hysterectomy, bilateral salpingectomy, and bilateral 
oophorectomy.  
 Women in the following cate gories are not considered women of c hildbearing potential  
 
1. Premenopausal female with one of the following:  
a) Documented hysterectomy  
b) Documented bilateral salpingectomy  
c) Documented bilateral oophorectomy  
 Note: Documentation can come from the site personnel’s: review of participant ’s medical records, medical 
examination, or medical history interview.  
 
2. Premenarchal  
 
3. Postmenopausal  female  
a) A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be us ed to confirm a 
postmenopausal state in women not using hormonal contraception or hormone  replacement therapy 
(HRT). However , in the absenc e of 12 months of amenorrhea, a single follicle stimulating hormone 
measurement is insufficient.  
b) Females on HRT and whose menopausal status is in doubt will be required to use 1 of the non -
hormonal highly effective contraception methods if they wish to continue their HRT during the study. 
Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study 
enrolment . 
Contraception Guidance  
Male  participants  
Male participants with female partners of childbearing potential are eligible to participate if they agree to the 
following:   
1. Are abstinent from penile- vaginal intercourse as their usual and preferred lifestyle (abstinent on a long-
term and persistent basis) and agree to remain abstinent for duration of study and for 4 days from last dose  
2. Female partner is using a highly effective contraceptive method   
3. Agree to use a male condom plus an additional method with a failure rate of <1% per year as described 
in the table below when having penile- vaginal intercourse with a woman of childbearing potential .   
4. Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile- vaginal 
intercourse or use a male condom during each episode of penile penetration and for 4 days from last 
dose.  
5. Refrain from donating sperm for duration of study and for 4 days from last dose.  
 Protocol Version 1.4  
 
 Page 55 of 59  
Highly Effective Contraceptive Methods That Are User Dependent   
Failure rate of <1% per year when used consistently and correctlya.  
 Combined (estrogen and progestogen -containing) hormonal contraception associated with inhibition of 
ovulationb  
• Oral  
• Intravaginal  
• Transdermal  
 Progestogen -only hormonal contraception associated with inhibition of ovulationb  
• Oral  
• Injectable  
Highly Effective Methods That Are User Independent   
• Implantable progestogen -only hormonal contraception associated with inhibition of ovulationb 
• Intrauterine device (IUD)  
• Intrauterine hormone- releasing system (IUS)  
• Bilateral tubal occlusion  
 Vasectom ized partner  
(A vasectom ized partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the woman of childbearing potential  and the absence of sperm has been confirmed. If not, 
an additional highly effective method of contraception  should be used. )  
 Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatment . The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant .)  
NOTES:  
a) Typical use failure rates may differ from those when used consistently and correct ly. Use should be 
consistent with local regulations regarding the use of contraceptive methods for participant s participating in 
clinical studies.  
b) Hormonal contraception may be susceptible to interaction with the study treatment , which may reduce the 
efficacy of the contraceptive method. In this case,  2 highly effective methods of contraception should be 
utilized during the treatment period and fo r at least 4 days from last dose.   
 
Female participants  
Female participant s of reproductive potential are eligible to participate if they agree to use a highly effective 
method of contraception consistently and correctly as described in the table above.   
Pregnancy Testing  
Women of childbearing potential  should onl y be includ ed after a confi rmed menstrua l period and a n egative 
highly sensitive serum pregnancy test. 
 
Addit ional pregnancy testing should be pe rformed at regular int ervals as per the SoA during the t reatment 
period and at 28 days after the last dose of stud y treatment. 
 Pregnancy testi ng will be p erformed wh enever a menstru al cycle is mis sed or when pre gnancy is 
otherwise suspected. 
 
Pregnancy testi ng, with a s ensitivity of 5 mIU/mL will be performed and assayed at the study site.   
 Protocol Version 1.4  
 
 Page 56 of 59 Collection of Pregnancy Information  
Male participant s with partners of reproductive potential who become pregnant  
 
Investigator will attempt to collect pregnancy information on a ny female partner of a m ale stu dy participant 
who be comes p regnant whi le participating in t his study. This applies onl y to pa rticipants who receive stu dy 
treatment. 
 
If a pregnancy is reported for a subject’s partner, study treatment  will be immediately discontinued.  
 
After obtaini ng the ne cessary signed ICF from the preg nant female p artner directly, the Investigator  will 
record pregnancy informa tion on the a ppropriate form and submit it to the DCC within 24 hours of  learning 
of the  partner’s pregnancy. 
 
Partner will also be foll owed to det ermine the ou tcome of the pre gnancy. Information on the status of the mot her 
and child will be fo rwarded to the DCC.  
 
Generally, follow- up will be no longer than 6 to 8 w eeks followin g the e stimated delivery date. Any termination 
of the p regnancy will be r eported rega rdless of f etal status (p resence or absence of anomalies) or indic ation 
for procedure. 
 
Female participants who become pregnant  
 Investigator will colle ct preg nancy information on any female participant who b ecomes preg nant whi le 
participating in t his study. 
 Information wil l be recorded on the appropriate form and submi tted to  the DCC within 24 hours of  learning of 
a participant 's pregnancy. 
 
Participant will be followe d to det ermine the out come of the p regnancy. The Investigator  will collect follow- up 
information on pa rticipant and neonate, which will be fo rwarded to the DCC . Generally, follow-up will not be 
required for longer  than 6 to 8 w eeks beyond the estimated delivery date. 
 
Any termination of pre gnancy will be r eported, regardless of f etal st atus ( presence or a bsence of 
anomalies ) or ind ication for procedure. 
 
While pregnancy itself is not considere d to be a n AE or SAE, a ny pregnancy comp lication or elective 
termination of a preg nancy will be r eported as an AE or SAE.  
A spont aneous abortion is always consid ered to be  an SAE and will  be reported as such.  
 
Any SAE occurring as a result of a pos t-study pre gnancy that is consid ered reasonably related to the stu dy 
treatment by the Investigator  will be r eported to the DCC as described in App endix 4. While the Investigator  is 
not obl igated to act ively seek this information in former stu dy participants, he/ she m ay learn of an SAE through 
spont aneous r eporting. 
 
Any female participant who bec omes pre gnant while participating will be withdrawn from the study.  
 
 
 
  
 Protocol Version 1.4 
 
 Page 57 of 59 Appendix  6:  Study Organization  
UAB  Name  Title Contact  
Study PI, Medical 
Oversight  Mark Dransfield, MD  Professor  205-996-0101  
mdransfield@uabmc.edu  
Study PI, DCC Oversight  Chichi Aban, PhD  Professor  205-934-2782  
caban@uab.edu  
Sub-Investigator  Mike Wells, MD  Associate 
Professor  205-996-0101  
jmwells@uabmc.edu  
Sub-Investigator   Gary Cutter, PhD  Professor  205-975-5048  
cutterg@uab.edu  
Financial and 
Subcontracting Oversight  Casondra Matthews  Clinical Research 
Administrator III  205-934-5555  
casondramatthews@uabmc.edu  
Regulatory Oversight  Elizabeth Westfall 
MPH  Director -Clinical 
Research 
Administration  205-934-9282  
ewestfall@uabmc.edu  
NIH/NCATS  
NCATS Oversight  Bobbie Ann Austin, 
PhD Program Officer  Ph: 301.435.0824  
bobbieann.mount@nih.gov  
NHLBI Oversight and 
Medical Monitor  Antonello (Tony) 
Punturieri, MD, PhD  Program Director, 
DLD at NHLBI  Ph: (301) 592 -8573  
punturieria@nhlbi.nih.gov  
Mereo BioPharma  
Mereo BioPharma Medical 
Expert and Sponsor 
Signatory  Jackie Parkin  Therapeutic Area 
Head Mereo BioPharma 4 Ltd.  
1 Cavendish Place  
London, W1G 0QF  
Mereo BioPharma Clinical 
Operations Oversight  William Moore  Clinical Operations  
Lead 
Participating Centers  
Cleveland Clinic  Jamie Stoller, MD, MS  
Umur Hatipoglu, MD  Site PI  
 Site Sub -Inv stollej@ccf.org  
 HATIPOU@ccf.org  
Temple University  Wissam Chatila, MD  Site PI  Wissam.Chatila@tuhs.temple.edu  
University of Texas Tyler  Megan Devine, MD  Site PI  Megan.Devine@uthct.edu  
Medical University of 
South Carolina  Charlie Strange, MD  Site PI  StrangeC@musc.edu  
National Jewish Health  Sandy Sandhaus, MD, 
PhD Site PI  Rsandhaus@alphanet.org  
University of North 
Carolina at Chapel Hill  M. Brad Drummond, 
MD, MHS  Site PI  brad_drummond@med.unc.edu  
 Protocol Version 1.4  
 
 Page 58 of 59 University of Utah  Cheryl Pirozzi, MD  Site PI  Cheryl.Pirozzi@hsc.utah.edu  
Columbia University  Jeanine M. D'Armiento, 
MD, PhD  Site PI  jmd12@cumc.columbia.edu  
Data Safety Monitoring Board  
Brendan McGuire, MD  Gastroenterologist, 
UAB bmcguire@uabmc.edu  
Robert Reed, MD  Pulmonologist, 
University of Maryland  rreed@som.umaryland.edu  
Amber Salter, PhD  Statistician, 
Washington University  amber@wustl.edu  
 
 
 
 Protocol Version 1.4  
 
 Page 59 of 59 Appendix  7:  Summary of Versions and Changes 
Protocol  Version  Date  Summary of Change  
Original  1.0 September 5 , 2018  Not Applicable 
Revision 1  1.1 October 26, 2018  Eligibility and safety modifications per FDA request (see 
also Table of Protocol changes October 26, 2018)  
Revision 2  1.2 July 31, 2019  Eligibility and safety modifications (see also Table of 
Protocol changes July 31, 2019)  
Revision 3  1.3 February 18, 2020  Eligibility modifications to include participants on 
augmentation therapy  and safety updates  (also see 
Table of Protocol changes February 18, 2020  
Revision 4  1.4 February 10, 2021  Eligibility modifications to include participants with other 
rare genotypes/phenotypes at increased risk for 
emphysema. (also see Table of Protocol changes 
February 16, 2021)  
 